[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 256
1. Cho KS, Choi YD, Kim SJ, Kim CI, Chung BH, Seong do H, Lee DH, Cho JS, Cho IR, Hong SJ: A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J; 2008 Jun 30;49(3):451-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: On univariate analysis, constitutional symptoms, sarcomatoid differentiation, tumor necrosis, multiple primary lesions, liver metastasis, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), thrombocytosis, alkaline phosphatase, hematocrit, T stage, N stage, and nuclear grade had significant influence on survival (p<0.05).
  • Multivariate analysis revealed the following features associated with survival: sarcomatoid differentiation [hazard ratio (HR)=2.99, p<0.001], liver metastasis (HR=2.09, p=0.002), ECOG-PS (HR=1.95, p=0.005), N stage (HR=1.94, p=0.002), and number of metastatic sites (HR=1.76, p=0.003).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunotherapy / methods. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Nephrectomy / methods. Prognosis. Retrospective Studies


2. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N, Yanagihara K, Yokozaki H: High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch; 2007 Mar;450(3):303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
  • Phosphatase of regenerating liver (PRL)-3, encoding a 22-kD low molecular weight tyrosine phosphatase, has been reported to be associated with metastasis of colorectal carcinoma.
  • High PRL-3 expression was detected in 36.2% of primary gastric carcinoma (with nodal metastasis, 55.6%; without nodal metastasis, 10%; P < 0.001) and in 74.1% of lymph node metastases.
  • The incidence of high PRL-3 expression in lymph node metastasis was significantly higher than in primary tumors (P < 0.044).
  • Moreover, high expression of PRL-3 was closely associated with tumor size, lymphatic invasion, venous invasion, extent of lymph node metastasis, and tumor stage.
  • PRL-3 might be a novel molecular marker for aggressive gastric cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Nodes. Male. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Neoplasm Staging. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Ther. 2002 Feb-Mar;93(2-3):307-17 [12191622.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8 [11355880.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1517-22 [16873432.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Int Rev Cytol. 2001;204:49-95 [11243597.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] Hybrid Hybridomics. 2004 Feb;23(1):23-7 [15000845.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(8):2444-8 [3162770.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12 ):3824-31 [12473596.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21444-52 [10747914.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Ann Surg. 1978 Dec;188(6):711-5 [736648.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Br J Surg. 1970 Dec;57(12):877-83 [5487028.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):179-83 [16472776.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3153-61 [16540666.001]
  • [Cites] J Histochem Cytochem. 1993 Apr;41(4):499-506 [8095509.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] FEBS Lett. 2004 May 7;565(1-3):181-7 [15135076.001]
  • [Cites] Cancer Lett. 2003 Dec 30;202(2):201-11 [14643450.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):347-54 [16832410.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):381-90 [1986233.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • (PMID = 17235563.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


3. Zhou L, Yang YP, Feng YY, Lu YY, Wang CP, Wang XZ, An LJ, Zhang X, Wang FS: Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study. Ai Zheng; 2009 Jan;28(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study.
  • BACKGROUND AND OBJECTIVE: Recent years, great progression has been made in treating primary hepatocellular carcinoma (HCC) with argon-helium cryosurgical ablation.
  • This study was to evaluate its efficacy on unresectable primary HCC.
  • METHODS: A total of 124 primary HCC patients were divided into early stage, middle stage and advanced stage groups according to BCLC staging classification.
  • The median survival time was 31.25 months in early stage group, 17.41 months in middle stage group and 6.82 months in advanced stage group.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cryosurgery / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Argon. Female. Helium. Humans. Liver / physiopathology. Male. Middle Aged. Pilot Projects. Postoperative Complications / epidemiology. Survival Rate. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • Hazardous Substances Data Bank. HELIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448416.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 206GF3GB41 / Helium; 67XQY1V3KH / Argon
  •  go-up   go-down


Advertisement
4. Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N: Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol; 2008 Apr;3(4):374-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
  • BACKGROUND: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway, has single agent activity in non-small cell lung cancer (NSCLC).
  • METHODS: chemotherapy-naive, stage IIIb (with pleural effusion) or IV NSCLC, Eastern Cooperative Oncology Group Performance Status (PS) 0-1.
  • The primary objective was to evaluate the overall response rate; secondary objectives included estimation of progression free survival, overall survival, and to assess the toxicity of this regimen.
  • RESULTS: From January 2004 to November 2004, 31 patients were enrolled: male/female 13/18; median age 70 years (range, 19-93); 68% had adenocarcinoma; Eastern Cooperative Oncology Group PS 0/1 13/18; stage IIIb/IV 2/29.
  • Two additional patients discontinued treatment due to adverse events (elevated liver enzymes).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Celecoxib. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pyrazoles / administration & dosage. Quinazolines / administration & dosage. Sulfonamides / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379355.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; S65743JHBS / gefitinib
  •  go-up   go-down


5. Kim H, Ahn YC, Park HC, Lim DH, Nam H: Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer. J Thorac Oncol; 2010 Apr;5(4):526-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer.
  • INTRODUCTION: Retrospective analyses were performed on the patients with primary or metastatic lung cancer, who were treated with hypofractionated stereotactic radiation therapy (HSRT).
  • METHODS: HSRT was applied to 43 patients since 2001 till 2007: 16 patients were with stage I primary lung cancer and 27 were with metastasis.
  • The 5-year local progression-free survival and cancer-specific survival rate were 89.4 and 53.3%, respectively.
  • CONCLUSIONS: In HSRT for primary or metastatic lung cancers, smaller tumor size was significant prognostic factor for higher local control.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Gastrointestinal Neoplasms / radiotherapy. Head and Neck Neoplasms / radiotherapy. Liver Neoplasms / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome


6. Ninos JM, Jefferies LC, Cogle CR, Kerr WG: The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. J Transl Med; 2006 Feb 16;4:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Thrombopoietin (TPO), the primary cytokine regulating megakaryocyte proliferation and differentiation, exerts significant influence on other hematopoietic lineages as well, including erythroid, granulocytic and lymphoid lineages.
  • We previously demonstrated that the receptor for TPO, c-mpl, is expressed by a subset of human adult bone marrow hematopoietic stem/progenitor cells (HSC/PC) that are enriched for long-term multilineage repopulating ability in the SCID-hu Bone in vivo model of human hematopoiesis.
  • METHODS: Here, we employ flow cytometry and an anti-c-mpl monoclonal antibody to comprehensively define the surface expression pattern of c-mpl in four differentiation stages of human CD34+ HSC/PC (I: CD34+38--, II: CD34+38dim, III: CD34+38+, IV: CD34dim38+) for the major sources of human HSC: fetal liver (FL), umbilical cord blood (UCB), adult bone marrow (ABM), and cytokine-mobilized peripheral blood stem cells (mPBSC).
  • RESULTS: For all tissue sources, the percentage of c-mpl+ cells was significantly highest in stage I HSC/PC (FL 72 +/- 10%, UCB 67 +/- 19%, ABM 82 +/- 16%, mPBSC 71 +/- 15%), and decreased significantly through stages II, III, and IV ((FL 3 +/- 3%, UCB 8 +/- 13%, ABM 0.6 +/- 0.6%, mPBSC 0.2 +/- 0.1%) [ANOVA: P < 0.0001].
  • The relative median fluorescence intensity of c-mpl expression was similarly highest in stage I, decreasing through stage IV [ANOVA: P < 0.0001].
  • Primary Thy/Liv grafts injected with CD34+38--/dimc-mpl+ cells showed slightly higher levels of donor HLA+ thymocyte reconstitution vs. CD34+38--/dimc-mpl---injected grafts and non-injected controls (c-mpl+ vs. c-mpl--: CD2+ 6.8 +/- 4.5% vs. 2.8 +/- 3.3%, CD4+8-- 54 +/- 35% vs. 31 +/- 29%, CD4--8+ 29 +/- 19% vs. 18 +/- 14%).
  • CONCLUSION: These findings support the hypothesis that the TPO receptor, c-mpl, participates in the regulation of primitive human HSC from mid-fetal through adult life.

  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Investig Med. 1998 Aug;46(6):303-11 [9737093.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):568-81 [9827938.001]
  • [Cites] Exp Hematol. 1999 Feb;27(2):302-12 [10029170.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):1-8 [10037043.001]
  • [Cites] Haematologica. 1999 Feb;84(2):167-76 [10091416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9118-23 [10430905.001]
  • [Cites] Exp Hematol. 1999 Sep;27(9):1418-27 [10480433.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2686-95 [10515872.001]
  • [Cites] Bone Marrow Transplant. 1999 Dec;24(11):1167-76 [10642804.001]
  • [Cites] Blood. 2000 May 1;95(9):2813-20 [10779426.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):71-81 [10930981.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1740-7 [10961872.001]
  • [Cites] Stem Cells. 1998;16 Suppl 1:113-22 [11012153.001]
  • [Cites] Blood. 2001 Jan 1;97(1):139-46 [11133753.001]
  • [Cites] Blood. 2001 Jan 15;97(2):383-7 [11154212.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Apr;10(2):273-81 [11359674.001]
  • [Cites] J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):62-7 [11388746.001]
  • [Cites] Blood. 2002 Jul 15;100(2):724-7 [12091376.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):303-4 [12163447.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):389-94 [12163458.001]
  • [Cites] Stem Cells. 2003;21(3):272-80 [12743322.001]
  • [Cites] Arthritis Rheum. 2003 Jun;48(6):1647-51 [12794833.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:17-25 [12799278.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:39-43 [12799280.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:141-51 [12799292.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:222-6 [12799299.001]
  • [Cites] J Hematother Stem Cell Res. 2003 Oct;12(5):473-89 [14594504.001]
  • [Cites] Stem Cells. 2004;22(3):334-43 [15153610.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Cell Prolif. 2004 Aug;37(4):295-306 [15245565.001]
  • [Cites] J Virol. 2004 Oct;78(20):11385-92 [15452260.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):625-30 [15577911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5640-4 [1608974.001]
  • [Cites] Blood. 1991 Mar 15;77(6):1218-27 [1705833.001]
  • [Cites] J Immunol. 1991 Jun 1;146(11):3751-6 [1827814.001]
  • [Cites] Annu Rev Immunol. 1991;9:399-429 [1910684.001]
  • [Cites] J Exp Med. 1990 Oct 1;172(4):1055-63 [2212942.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1632-9 [2971269.001]
  • [Cites] Cytometry. 1988 Nov;9(6):619-26 [3061754.001]
  • [Cites] J Immunol. 1984 Jul;133(1):157-65 [6586833.001]
  • [Cites] Blood. 1994 Jul 15;84(2):421-32 [7517715.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3308-13 [7579432.001]
  • [Cites] Blood. 1993 Sep 1;82(5):1395-401 [7689867.001]
  • [Cites] Oncogene. 1993 Oct;8(10):2607-15 [8397366.001]
  • [Cites] Blood. 1996 Jan 1;87(1):1-13 [8547630.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2162-70 [8630375.001]
  • [Cites] Exp Hematol. 1996 Feb;24(2):265-9 [8641351.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1470-4 [8643656.001]
  • [Cites] N Engl J Med. 1996 Jul 18;335(3):157-66 [8657213.001]
  • [Cites] J Exp Med. 1996 Jun 1;183(6):2551-8 [8676076.001]
  • [Cites] Blood. 1996 Aug 1;88(3):803-8 [8704234.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2859-70 [8874182.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4102-9 [8943843.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1329-37 [8946831.001]
  • [Cites] Exp Hematol. 1997 Jan;25(1):1-7 [8989900.001]
  • [Cites] Bone Marrow Transplant. 1997 Jun;19(12):1175-81 [9208110.001]
  • [Cites] N Engl J Med. 1997 Aug 7;337(6):373-81 [9241126.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2282-92 [9310479.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1337-45 [9396603.001]
  • [Cites] Blood. 1998 Jan 1;91(1):353-9 [9414305.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4145-51 [9596660.001]
  • [Cites] Stem Cells. 1998;16(3):153-65 [9617891.001]
  • [Cites] Blood. 1998 Jul 1;92(1):4-10 [9639492.001]
  • [Cites] Bone Marrow Transplant. 1998 Jul;22 Suppl 1:S56 [9715889.001]
  • (PMID = 16480521.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R21 AG044333; United States / NCI NIH HHS / CA / T32 CA009140; United States / NHLBI NIH HHS / HL / T32 HL007775; United States / NINDS NIH HHS / NS / P01 NS027405; United States / NHLBI NIH HHS / HL / R01 HL072523
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1402332
  •  go-up   go-down


7. Rochet N, Jensen AD, Sterzing F, Munter MW, Eichbaum MH, Schneeweiss A, Sohn C, Debus J, Harms W: Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol. BMC Cancer; 2007 Dec 19;7:227
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.
  • BACKGROUND: The prognosis for patients with advanced epithelial ovarian cancer remains poor despite aggressive surgical resection and platinum-based chemotherapy.
  • Despite the clinically proven efficacy of whole abdominal irradiation, the use of radiotherapy in ovarian cancer has profoundly decreased mainly due to high treatment-related toxicity.
  • Modern intensity-modulated radiation therapy (IMRT) could allow to spare kidneys, liver, and bone marrow while still adequately covering the peritoneal cavity with a homogenous dose.
  • Patients with advanced ovarian cancer stage FIGO III (R1 or R2< 1 cm) after surgical resection and platinum-based chemotherapy will be treated with whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions.
  • For treatment planning bone marrow, kidneys, liver, spinal cord, vertebral bodies and pelvic bones are defined as organs at risk.
  • DISCUSSION: The primary endpoint of the study is the evaluation of the feasibility of intensity-modulated WAI and the evaluation of the study protocol.
  • The aim is to explore the potential of IMRT as a new method for WAI to decrease the dose to kidneys, liver, bone marrow while covering the peritoneal cavity with a homogenous dose, and to implement whole abdominal intensity-modulated radiotherapy into the adjuvant multimodal treatment concept of advanced ovarian cancer FIGO stage III.
  • [MeSH-minor] Adult. Aged. Clinical Protocols. Dose Fractionation. Endpoint Determination. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging. Organ Specificity. Patient Selection. Pilot Projects. Radiation Injuries / prevention & control. Research Design. Risk

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1999 Dec;53(3):213-8 [10660201.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:3-11 [15839952.001]
  • [Cites] Forum (Genova). 2000 Oct-Dec;10(4):335-52 [11535984.001]
  • [Cites] Front Radiat Ther Oncol. 2002;36:25-34 [11842752.001]
  • [Cites] Radiother Oncol. 2002 Feb;62(2):163-71 [11937243.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1330-7 [11955746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):278-89 [12183002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21 [12527043.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):313-21 [12742271.001]
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):278-86 [12801256.001]
  • [Cites] Radiologe. 2003 Jun;43(6):448-54 [12827259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):516-21 [12957265.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):535-41 [14509952.001]
  • [Cites] Br J Radiol. 2003 Oct;76(910):673 [14512325.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):e136-43 [14528088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1019-32 [14575833.001]
  • [Cites] Acta Oncol. 2003;42(5-6):562-6 [14596514.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:241-50 [14656286.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66 [14763172.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2755-6 [15187058.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 May;8(5):893-7 [7107423.001]
  • [Cites] Cancer. 1985 May 1;55(9 Suppl):2285-90 [3919934.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):607-13 [2777649.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1203-6 [2254113.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1990 Jan;2(1):4-9 [2261388.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):30-5 [2026356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):835-45 [1555974.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):847-51 [1555975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):853-8 [1555976.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1710-8 [8431909.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):26-32 [8438083.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii36-viii38 [16239235.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii7-viii12 [16239238.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1641-3; author reply 1641-3 [16611959.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):276-82 [16546279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Oct;4(9):912-39 [17020669.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):783-92 [17070570.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Recent Results Cancer Res. 2007;174:91-100 [17302189.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):97-103 [8244182.001]
  • [Cites] Semin Oncol. 1995 Jun;22(3 Suppl 6):78-83 [7541158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):543-9 [9635700.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):215-9 [10021304.001]
  • [Cites] Cancer Invest. 2004;22 Suppl 2:11-20 [15573741.001]
  • [Cites] Cancer Invest. 2004;22(5):815-7 [15581063.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):389-94 [15661226.001]
  • [Cites] Br J Radiol. 2000 May;73(869):459-69 [10884741.001]
  • (PMID = 18093313.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2212657
  •  go-up   go-down


8. Malmström A, Hansen J, Malmberg L, Carlsson L, Svensson JH, Ahlgren J, Ahlin C, Jansson T, Westberg R: Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study. Acta Oncol; 2010;49(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
  • AIM: The aim of this study was to explore the clinical value of gemcitabine combined with capecitabine (GC) in heavily pre-treated patients with metastatic breast cancer.
  • In 14 patients (41%), more than two metastatic sites were diagnosed with bone (68%) and liver (62%) being the most prominent.
  • The primary objective was to investigate time to progression.
  • DISCUSSIONS: We investigated the value of the GC combination as a treatment for late stage breast cancer patients.
  • [MeSH-minor] Adult. Aged. Anthracyclines / therapeutic use. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Kaplan-Meier Estimate. Middle Aged. Salvage Therapy. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839920.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Limmer S, Oevermann E, Killaitis C, Kujath P, Hoffmann M, Bruch HP: Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer. Langenbecks Arch Surg; 2010 Nov;395(8):1129-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer.
  • BACKGROUND: Resection of isolated hepatic or pulmonary metastases from colorectal cancer is widely accepted and associated with a 5-year survival rate of 25-40%.
  • Of 73 patients identified with resection of CRC and, at some point in time, both liver and lung metastases, 17 patients underwent metastasectomy (resection group).
  • Primary tumour, hepatic and pulmonary metastases of all patients were surgically treated in our department of surgery, and the results are that of a single institution.
  • Independent from the chronology of metastasectomy, 5-year survival was 55% with respect to the primary resection, 28% with respect to the first metastasectomy and 14% with respect to the second metastasectomy.
  • A disease-free interval (>18 months), stage III (UICC) and age (<70 years) were found to be significant prognostic factors for overall survival.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1751-8 [11919231.001]
  • [Cites] Ann Thorac Surg. 2007 Jul;84(1):324-38 [17588454.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Nov;124(5):1007-13 [12407386.001]
  • [Cites] J Am Coll Surg. 2003 Sep;197(3):386-91 [12946793.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Sep;126(3):732-9 [14502146.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S22-31 [14530655.001]
  • [Cites] Ann R Coll Surg Engl. 2003 Sep;85(5):334-9 [14594539.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Feb;25(2):151-4 [14747104.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):238-44 [15223436.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Dis Colon Rectum. 1979 Nov-Dec;22(8):553-6 [527448.001]
  • [Cites] Cancer Metastasis Rev. 1984;3(4):303-24 [6394125.001]
  • [Cites] Ann Surg. 1987 Mar;205(3):256-63 [3827361.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1407-18 [2476530.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):62-7 [1994607.001]
  • [Cites] Surg Gynecol Obstet. 1992 Jan;174(1):27-32 [1729745.001]
  • [Cites] Ann Thorac Surg. 1992 May;53(5):780-5; discussion 785-6 [1570970.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Nov;106(5):875-9 [8231210.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):94-6 [8313135.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Dec;118(6):1090-6 [10595983.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):975-9; discussion 979-80 [11269484.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):607-9 [11801764.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2047-53 [8683235.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):274-8 [9445182.001]
  • [Cites] Ann Thorac Surg. 1998 Jul;66(1):214-8; discussion 218-9 [9692467.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):66-75; discussion 75-6 [9869759.001]
  • [Cites] Int Surg. 1998 Oct-Dec;83(4):340-2 [10096757.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):241-3 [10100795.001]
  • [Cites] Langenbecks Arch Surg. 1999 Aug;384(4):313-27 [10473851.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7125-34 [16192596.001]
  • [Cites] J Am Coll Surg. 2006 Mar;202(3):468-75 [16500252.001]
  • [Cites] Thorac Surg Clin. 2006 May;16(2):145-55, vi [16805204.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1538-44 [17009154.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1164-8 [12190683.001]
  • (PMID = 20165954.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2974188
  •  go-up   go-down


10. Li XP, Meng ZQ, Guo WJ, Li J: Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol; 2005 Jun 28;11(24):3782-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for liver metastases from breast cancer: results and prognostic factors.
  • AIM: Liver metastases from breast cancer (BCLM) are associated with poor prognosis.
  • We report the results of TACE and systemic chemotherapy for patients with liver metastases from breast cancer and evaluate the prognostic factors.
  • METHODS: Forty-eight patients with liver metastases, from proved breast primary cancer were treated with TACE or systemic chemotherapy between January 1995 and December 2000.
  • According to univariate analysis, variables significantly associated with survival were the lymph node status of the primary cancer, the clinical stage of liver metastases, the Child-Pugh grade, loss of weight.
  • Other factors such as age, the intervals between the primary to the metastases, the maximal diameter of the liver metastases, the number of liver metastases, extrahepatic metastasis showed no prognostic significances.
  • These factors mentioned above such as the lymph node status of the primary cancer, the clinical stage of liver metastases, the Child-Pugh grade, loss of weight were also independent factors in multivariate analysis.
  • CONCLUSION: TACE treatment of liver metastases from breast cancer may prolong survival in certain patients.
  • This approach offers new promise for the curative treatment of the patients with metastatic breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Chemoembolization, Therapeutic. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Gastroenterol. 2005 Nov 28;11(44):7057 [16437619.001]
  • (PMID = 15968739.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC4316035
  •  go-up   go-down


11. Zhu Lz, Yang Rj: [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage]. Beijing Da Xue Xue Bao; 2008 Apr;40(2):129-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage].
  • CONCLUSION: Primary hepatic carcinoma with AVS increases difficulty of interventional therapyìbut as long as we take active and proper treating measureìwe could acquire satisfactory curative effect without serious syndrome.
  • DSA can demonstrate the type, the site and the degree of AVS completely and directly, thus having important value in treating primary hepatic carcinoma and improving prognosis.
  • [MeSH-major] Angiography, Digital Subtraction. Arteriovenous Fistula / radiography. Arteriovenous Fistula / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / radiography. Female. Hepatic Artery / abnormalities. Humans. Male. Middle Aged. Portal Vein / abnormalities. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458684.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Park IJ, Kim HC, Yu CS, Kim PN, Won HJ, Kim JC: Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol; 2008 Jan;15(1):227-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery.
  • BACKGROUND: We compared outcomes of surgery and radiofrequency thermal ablation (RFA) in patients with metachronous liver metastases.
  • METHODS: Between October 1995 and December 2005, 59 patients underwent hepatic resection and 30 underwent RFA for metachronous liver metastases.
  • RESULTS: The two groups had similar mean age, sex ratio, comorbid medical conditions, primary disease stage, and frequency of solitary metastases.
  • CONCLUSIONS: Compared with hepatic resection, RFA for metachronous hepatic metastases from colorectal cancer was associated with higher local recurrence and shorter recurrence-free and overall survival rates, even in patients with solitary, small (</=3 cm) lesions.
  • [MeSH-major] Catheter Ablation. Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiology, Interventional. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome


13. Liu XB, Yuan ZY, Song YC, Li FT, Dong Y, Wang JS, Li XY, Wang P: [An initial report of cyberknife radiosurgery for primary hepatic carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An initial report of cyberknife radiosurgery for primary hepatic carcinoma].
  • OBJECTIVE: To study the efficacy and toxicity of cyberknife radiosurgery for primary hepatic carcinoma.
  • METHODS: From September 2006 to March 2008, 17 patients with clinical stage I-III primary hepatic carcinoma were treated with cyberknife at Tianjin Cancer Hospital.
  • Totally 23 lesions in the liver were treatment.
  • All the lesions in liver treated by the cyberknife radiosurgery achieved local control.
  • CONCLUSION: The cyberknife radiosurgery for primary hepatic carcinoma showed a high rate of local control and minimal toxicity.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Female. Fiducial Markers. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450595.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


14. Yan K, Wang YB, Chen MH, Gao W, Yang W, Dai Y, Yin SS: [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors]. Zhonghua Yi Xue Za Zhi; 2005 Aug 31;85(33):2322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors].
  • OBJECTIVE: To investigate the prognostic factors affecting outcome in Radiofrequency (RF) ablation of primary hepatic tumors by univariate and multivariate analyses, and to assess the therapeutic efficacy of Radio-frequency ablation.
  • METHODS: A total of 172 patients with primary hepatic tumors underwent RF treatment in our department between 1999 and 2004.
  • These 8 factors were Child-Pugh grade, UICC stage, AFP value before first RF, Portal hypertension, first treatment or treatment for recurrence, pathological grade, treatment purpose and method, ablative safe margin.
  • For 116 patients who underwent RF when first diagnosis, the survival rates in patients with different tumor stage (UICC standard of hepatocellular carcinoma) at half a year, 1 year, 2 year and 3 year were estimated as follows: 96.7%, 92.3%, 81.6% and 65.3% in 33 patients of stage I-II; 91.2%, 76.3%, 56.6% and 51.4% in 83 patients of stage III-IV; There was significant difference in survival rates between patients of stage I-II and patients of stage III-IV.
  • For 56 patients suffered from recurrent hepatic tumors, the survival rates at half a year, 1 year, 2 year and 3 year were 88.5%, 70.2%, 41.4% and 24.5%, being similar to those of stage III-IV.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321224.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


15. Vujanić GM, Kelsey A, Perlman EJ, Sandstedt B, Beckwith JB: Anaplastic sarcoma of the kidney: a clinicopathologic study of 20 cases of a new entity with polyphenotypic features. Am J Surg Pathol; 2007 Oct;31(10):1459-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors were identified by re-reviewing tumors with unusual anaplastic features from the National Wilms Tumor Study Pathology Center, the International Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group trials.
  • Tumor stage was known in 15 patients including 7 stage I, 4 stage II, 3 stage III, and 1 stage IV tumors.
  • Of the 13 patients with a minimum of 2 years follow-up, 4 patients developed distant metastases and 1 had local recurrence including 1 patient with stage IV, 2 with stage III, and 2 with stage I at presentation.
  • One patient with stage I tumor developed widespread metastases and died.
  • Another stage I patient developed local recurrence after 3 months of diagnosis, but was lost to follow-up.
  • Five stage I patients were alive and free of tumor at last follow-up.
  • The most common sites of metastases were lung (3 cases), and liver and bones (2 cases each).
  • These tumors showed pathologic features similar to the pleuropulmonary blastoma of childhood and undifferentiated (embryonal) sarcoma of the liver.
  • In the differential diagnosis, anaplastic Wilms tumor, primary renal synovial sarcoma, malignant mesenchymoma, ectomesenchymoma, and mesenchymal chondrosarcomas have been considered but none of these tumors shared the same features as the 20 cases described here which represent a distinct clinicopathologic entity with morphologic features of a polyphenotypic anaplastic sarcoma of the kidney.
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Desmin / analysis. Disease-Free Survival. Female. Gene Expression. Humans. Immunoenzyme Techniques. Infant. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Nephrectomy. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Phenotype. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895746.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / SYT-SSX fusion protein; 0 / Vimentin
  •  go-up   go-down


16. Jing Z, Nan KJ, Hu ML: Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol; 2005 Apr 7;11(13):1910-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) The average proliferating index and apoptotic index in HCC were significantly higher than that in adjacent liver tissues.
  • The apoptotic index was significantly lower in TNM stage I-II than in stage III-IV.
  • (2) The level of p27 in the cytoplasmic fraction was higher in non-tumoral liver tissues and was associated with clinical stage;.
  • (3) Survival analysis showed advanced stage (P = 0.031) and with extrahepatic metastasis (P = 0.045) was significantly associated with shorter survival.
  • The combined examination of p27, and p53 expression allows reliable estimation of prognosis for patients with primary hepatic carcinoma.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Hepatocellular / metabolism. Cell Cycle Proteins / metabolism. Liver Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Division / physiology. Cyclin-Dependent Kinase Inhibitor p27. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800979.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC4305710
  •  go-up   go-down


17. Zhang CY, Huang TR, Yu JH, Zhang ZQ, Li JL, Deng W, Ye SY, Zhou DN, He ZF: Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China. Chin J Cancer; 2010 May;29(5):545-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China.
  • BACKGROUND AND OBJECTIVE: In Guangxi province, from 1970s to 1990s, the mortality of primary liver cancer (PLC) ranked the first among a variety of malignant tumors.
  • METHODS: Multi stage stratified cluster random sampling method was used to select 9 counties (cities or urban areas) as sample points.
  • [MeSH-major] Liver Neoplasms / epidemiology. Liver Neoplasms / mortality. Mortality / trends
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. China / epidemiology. Female. Humans. Infant. Male. Middle Aged. Sex Distribution. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426906.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


18. Puleo S, Zappalà O, Portale TR, Consoli A, Li Destri G: [Correlation between positive lymph nodes and metastasis of colorectal cancer. Personal experience]. Suppl Tumori; 2005 May-Jun;4(3):S16-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between positive lymph nodes and metastasis of colorectal cancer. Personal experience].
  • The authors, in a group of 190 patients treated with curative surgery for colorectal cancer, have studied the correlation between lymph nodes positive of primary tumor and rising of liver metastases.
  • Even if the B2 stage nodes were negative, liver metastases were found in 6.25% of the patients probably due to an understaging; in C1 + C2 stage the rate of liver metastases was 28.1%, however in this group has not been demonstrated a statistical correlation with the number of positive nodes as a predictive negative prognostic factor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437877.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, Haga H, Matsushita M, Ozaki M, Matsuno Y, Todo S: Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep; 2010 Aug;24(2):537-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD133 antigen has been used to identify cancer stem cells in several solid tumor types, including hepatocellular carcinomas (HCCs).
  • Tissue specimens from 136 HCC patients who underwent curative primary hepatectomy between 2000 and 2005 were collected and immunohistochemically analyzed for CD133 expression.
  • Positive cytoplasmic expression of CD133 was found to be associated with the overall survival of HCC patients, especially in stage III and IVA HCC patients (p=0.0092).
  • Patients with stage III and IVA HCC showing positive cytoplasmic expression of CD133 are more likely to have a worse prognosis.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma, Hepatocellular / mortality. Glycoproteins / metabolism. Liver Neoplasms / mortality. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cytoplasm / metabolism. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596644.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


20. Kawamura Y, Ikeda K, Kumada H: [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin]. Gan To Kagaku Ryoho; 2010 Mar;37(3):402-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A number of molecular-based chemotherapeutic agents are expected to become available in the future, and the primary therapy of advanced stage HCC may change with the introduction of these drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Platinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Chemoembolization, Therapeutic. Drug Resistance, Neoplasm. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332675.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Platinum Compounds; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


21. Loftås P, Onnesjö S, Widegren E, Adell G, Kayed H, Kleeff J, Zentgraf H, Sun XF: Expression of FXYD-3 is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of FXYD-3 is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy.
  • METHODS AND MATERIALS: The study included 140 rectal cancer patients who participated in a clinical trial of preoperative RT, 65 with and 75 without RT before surgery.
  • FXYD-3 expression was immunohistochemically examined in distant (n = 70) and adjacent (n = 101) normal mucosa, primary tumors (n = 140), and lymph node metastasis (n = 36).
  • In the RT group, strong FXYD-3 expression alone (p = 0 .02) or combined with phosphatase of regenerating liver was associated with an unfavorable prognosis (p = 0.02), independent of both TNM stage and tumor differentiation.
  • FXYD-3 expression in the primary tumors tended to be increased compared with normal mucosa regardless of RT.
  • CONCLUSION: FXYD-3 expression was a prognostic factor independent of tumor stage and differentiation in patients receiving preoperative RT for rectal cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chi-Square Distribution. Female. Humans. Intestinal Mucosa / metabolism. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Rectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289258.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / FXYD3 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A1 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


22. Schulz-Utermoehl T, Spear M, Pollard CR, Pattison C, Rollison H, Sarda S, Ward M, Bushby N, Jordan A, Harrison M: In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos; 2010 Oct;38(10):1688-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro metabolism of cediranib (4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline), a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) of all three VEGF receptors in late-stage development for the treatment of colorectal cancer and recurrent glioblastoma was investigated in hepatic proteins from preclinical species and humans using radiolabeled material.
  • The primary oxidative pathways were di-and trioxidations and pyrrolidine N-oxidation.
  • Additional metabolism studies in liver microsomes from these or other preclinical species (CD-1 mouse, Han Wistar rat, Dunkin Hartley guinea pig, Göttingen mini-pig, New Zealand White rabbit, beagle dog, and cynomolgus and rhesus monkey) indicated that the N(+)-glucuronide metabolite was not formed in these additional species.
  • [MeSH-major] Liver / enzymology. Liver / metabolism. Quinazolines / pharmacokinetics. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adult. Animals. Cells, Cultured. Cytochrome P-450 Enzyme System / metabolism. Dogs. Female. Glucuronosyltransferase / metabolism. Guinea Pigs. Hepatocytes / enzymology. Hepatocytes / metabolism. Humans. Macaca fascicularis. Macaca mulatta. Male. Metabolic Detoxication, Phase I. Metabolic Detoxication, Phase II. Mice. Microsomes, Liver / enzymology. Microsomes, Liver / metabolism. Middle Aged. Oxygenases / metabolism. Rabbits. Rats. Rats, Wistar. Species Specificity. Swine. Swine, Miniature

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20634336.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.13.- / Oxygenases; EC 1.14.13.8 / dimethylaniline monooxygenase (N-oxide forming); EC 2.4.1.17 / Glucuronosyltransferase; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; NQU9IPY4K9 / cediranib
  •  go-up   go-down


23. Xu J, Liu J, Guo JX, Ma HB, Zhao J, Liu AX, Xu WN, Li BA, Mao YL: [Evaluation on clinical value of serum CA-125 level in hepatitis cirrhosis]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Oct;24(5):334-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the association between elevated levels of serum cancer antigen (CA) 125 and hepatitis cirrhosis in different stage, and also to explore the clinical application value of serum CA-125.
  • RESULTS: Serum CA-125 levels were correlated closely with ascites, primary peritonitis and liver function Child-Paugh classification, but no associated with primary carcinoma of liver and other liver function index,such as ALT, AST, ALB, TBIL and PT.
  • CONCLUSION: The levels of serum CA-125 in hepatitis cirrhosis patients were osculating correlating with lesion of liver and ascite degree, could serve as a sensitive and conventional laboratory index for liver lesion degree and monitoring ascite generation.
  • It was necessary to further study on the association with serum CA-125 level with primary hepatic carcinoma.
  • [MeSH-major] CA-125 Antigen / blood. Liver Cirrhosis / blood. Liver Cirrhosis / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascites / pathology. Female. Humans. Liver / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21280316.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


24. Czeczot H, Scibior-Bentkowska D, Skrzycki M, Majewska M, Podsiad M: [Lipid peroxidation level in gastrointestinal tract tumors]. Pol Merkur Lekarski; 2010 Nov;29(173):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intensification of the lipid peroxidation process is a factor which may also lead to a malfunction in the antioxidant barrier, which further weakens the defense of cells against oxygen free radicals and promotes the onset and development of cancer.
  • The aim of the study was the determination of lipid peroxidation level in gastrointestinal tract tumors (stomach, liver, colon, and colorectal cancer to liver metastases).
  • MATERIAL AND METHODS: Materials for studies were obtained from 150 patients with gastrointestinal tract tumors: 10 with stomach cancer, 30 with malignant and benign liver cancers, 60 with primary colorectal cancer, and 50 with metachronous colorectal cancer liver metastases.
  • We also investigated 25 patients with liver cirrhosis, which was treated as a pre-cancerous condition.
  • Additionally, liver specimens were collected from patients with liver cirrhosis.
  • RESULTS: The study showed the highest concentration of TBARS in benign, and the lowest in malignant liver tumors.
  • TBARS concentration in these tumors was approximately 2-fold higher than in malignant liver tumors and much lower than in benign tumors.
  • In all cancers of the digestive tract with the exception of malignant liver tumors increased level of TBARS was found, comparing with control tissue.
  • The concentration of TBARS in cirrhotic liver was lower than in control.
  • The level of lipid peroxidation in liver cirrhosis and malignant liver tumors was similar.
  • The highest concentration of TBARS was found in G1 grade of colorectal cancer.
  • The highest level of lipid peroxidation, expressed as the concentration of TBARS was found in the I stage of colorectal cancer clinical advancement.
  • The significantly lowest concentration of TBARS was shown for stage II (UICC).
  • The changes of lipid peroxidation level--a marker of oxidative stress in gastrointestinal tumors appear to be closely associated with their development stages (liver cirrhosis/malignant liver cancer; colorectal cancer/colorectal cancer liver metastases) and are likely to create such conditions, in which cancerous cells may proliferate, undergo gradual dedifferentiation and malignancy, and generate metastases.
  • [MeSH-major] Gastrointestinal Neoplasms / metabolism. Lipid Peroxidation. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver Cirrhosis / metabolism. Male. Middle Aged. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21268915.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


25. Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL: Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer; 2007 Sep 3;97(5):582-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary end point was patient survival; secondary end points were the impact of therapy on tumour response, quality of life and variceal bleeding episodes.
  • Variables associated with a better survival in the multivariate analysis were: presence of cirrhosis, alpha-FP level <400 ng ml(-1) and Okuda stage I.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diarrhea / chemically induced. Female. Humans. Male. Middle Aged. Multivariate Analysis. Nausea / chemically induced. Neoplasm Staging. Octreotide / administration & dosage. Octreotide / adverse effects. Patient Compliance / statistics & numerical data. Prognosis. Quality of Life. Survival Analysis. Tamoxifen / administration & dosage. Tamoxifen / adverse effects. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998;77(1):115-22 [9459155.001]
  • [Cites] Digestion. 1996;57 Suppl 1:29-33 [8813463.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12(2):111-26 [9692685.001]
  • [Cites] Lancet. 1998 Jul 4;352(9121):17-20 [9800740.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1284-92 [10189133.001]
  • [Cites] Gut. 1999 Nov;45(5):766-74 [10517918.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1361-9 [15565568.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):694-701 [15763644.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1408-14 [15744746.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4338-46 [15994145.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1435-48 [16530734.001]
  • [Cites] Hepatology. 2007 Jan;45(1):9-15 [17187405.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):218-22 [10638587.001]
  • [Cites] Hepatology. 2000 Jan;31(1):54-8 [10613728.001]
  • [Cites] Am J Gastroenterol. 2007 Jul;102(7):1397-405 [17488248.001]
  • [Cites] Int J Oncol. 2000 Jun;16(6):1197-201 [10811995.001]
  • [Cites] J Hepatol. 2000 Nov;33(5):846-52 [11097497.001]
  • [Cites] Bull Cancer. 2000 Dec;87(12):881-6 [11174117.001]
  • [Cites] Mol Pathol. 2001 Jun;54(3):138-44 [11376124.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Z Gastroenterol. 2002 Jun;40(6):395-400 [12055662.001]
  • [Cites] Oncol Rep. 2002 Jul-Aug;9(4):903-7 [12066229.001]
  • [Cites] Hepatology. 2002 Sep;36(3):687-91 [12198662.001]
  • [Cites] Hepatogastroenterology. 2002 Sep-Oct;49(47):1245-50 [12239914.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S136-49 [12591191.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jun;129(6):327-34 [12811549.001]
  • [Cites] Acta Gastroenterol Belg. 2004 Jan-Mar;67(1):14-25 [15149081.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1474-84 [15196530.001]
  • [Cites] Gut. 2004 Aug;53(8):1180-9 [15247189.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):112-8 [15246216.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Endocrinology. 1992 Nov;131(5):2479-81 [1385103.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Aug 30;203(1):253-9 [8074663.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6334-7 [7987824.001]
  • [Cites] Hepatology. 1995 Jun;21(6):1535-42 [7768497.001]
  • [Cites] Gut. 1998 Mar;42(3):442-7 [9577356.001]
  • (PMID = 17687341.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 094ZI81Y45 / Tamoxifen; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2360361
  •  go-up   go-down


26. Park JW: [Hepatocellular carcinoma in Korea: introduction and overview]. Korean J Gastroenterol; 2005 Apr;45(4):217-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HCC accounts for over 80% of all primary liver cancers which ranks fourth among the organ-specific causes of cancer-related deaths worldwide.
  • Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) or presence of liver cirrhosis are important risk factors for HCC development globally.
  • Recently, five year survival rate of primary liver cancer is 9.6% in Korea.
  • Such poor prognosis of HCC results from the late detection of cancer, an aggressive tumor biology and underlying chronic liver diseases.
  • Because almost eighty percent of HCC is diagnosed in late stage, we launched a nationwide surveillance program to screen high risk groups (HBV or HCV carriers or liver cirrhosis, over 40 years old) and formulated the Korean practice guideline for the diagnosis and treatment of HCC with special emphasis on advanced stage of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Prevalence. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843747.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


27. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N, Hiura M, Sakamoto A, Tsuda H, Fukunaga M, Kamura T: Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol; 2007 Jul 1;25(19):2798-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-eight patients having EC at presumed stage IA and 17 patients with AH at younger than 40 years of age were enrolled.
  • The primary end point was a pathologic complete response (CR) rate.
  • Neither therapeutic death nor irreversible toxicities were observed; however, two patients had grade 3 body weight gain, and one patient had grade 3 liver dysfunction.
  • [MeSH-minor] Adult. Aspirin / pharmacology. Disease-Free Survival. Female. Humans. Pregnancy. Pregnancy Outcome. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602085.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] C2QI4IOI2G / Medroxyprogesterone Acetate; R16CO5Y76E / Aspirin
  •  go-up   go-down


28. Krstevska V, Stojkovski I, Zafirova-Ivanova B: Factors influencing the development of distant metastases in patients with head and neck squamous cell carcinoma. J BUON; 2010 Oct-Dec;15(4):690-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Univariate analysis demonstrated that the risk of DM was significantly influenced by age (p=0.047), cigarette smoking (p=0.024), ECOG performance status (PS) (p=0.008), location of the primary site (p=0.003), N stage (p<0.0001), overall stage (p<0.0001), histological differentiation (p<0.0001), levels of nodal involvement (p<0.0001), treatment modality (p<0.0002), presence of locoregional recurrence (LRR) (p<0.0001), and time to LRR (p<0.0001).
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate


29. Belev N, Takorov I, Dimov P, Vladov N, Penov V: Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer. J BUON; 2007 Apr-Jun;12(2):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer.
  • PURPOSE: The purpose of this study was to analyze the impact of aggressive surgery concerning resection of liver metastases (LMs) from colorectal cancer (CRC) on morbidity, mortality and survival rates and to establish the benefits of multimodal strategies in increasing the resectability rates of LMs.
  • Thirty-four (18.4%) of them had LMs at the time of initial diagnosis, and 26 patients developed LMs in a certain period of time after resection of the primary CRC.
  • RESULTS: 44 resections were performed in 29 patients: one-stage resection of the primary CRC and the LMs in 15 (40%) cases, resection and thermoablation after adjuvant chemotherapy in 2 (4.3%), resection after neoadjuvant chemotherapy in 8 (17.2%), two-stage liver resection in 1 (2.15%), resection after recurrence or because of a newfound LM in 3 (6.45%).
  • Five resections of metastases larger than 5 cm, and 4 resections of 4 or more liver metastases were performed.
  • Morbidity rate was 15.9% (bile leakage in 4 patients, liver abscess in 1 and wound disruption in 2).
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Survival Rate


30. Konishi K, Yamamoto H, Mimori K, Takemasa I, Mizushima T, Ikeda M, Sekimoto M, Matsuura N, Takao T, Doki Y, Mori M: Expression of C4.4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer. Cancer Sci; 2010 Oct;101(10):2269-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of C4.4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer.
  • The aim of this study was to explore the expression and clinical relevance of C4.4A in colorectal cancer.
  • By quantitative RT-PCR, 154 colorectal cancer tissues were examined for C4.4A mRNA.
  • We examined 132 colorectal cancer tissues by immunohistochemistry using a new polyclonal antibody that recognizes the C4.4A protein C-terminus containing the glycosylphosphatidyl-inositol anchor signaling sequence.
  • Immunohistochemistry showed strong membranous staining of C4.4A at the invasive front of colorectal cancer tumors and at the frontier of metastatic lesions to lymph node and lung.
  • The membranous staining with enhanced intensity at the invasive front of the primary colorectal cancer (Type A: 34/132, 25.6%) was associated with depth of invasion (P = 0.033) and venous invasion (P = 0.003), and was a significant independent prognostic factor (5-year overall survival in the entire series [n = 132; P = 0.004] and disease-free survival in stage II and III colorectal cancers [n = 82; P = 0.003]).
  • Moreover, Type A C4.4A expression was linked to shorter liver metastasis-free survival rate, lung metastasis-free survival rate, or hematogenous metastasis-free survival (P = 0.0279, P = 0.0061, and P = 0.0006, respectively).
  • Our data indicate that expression of the C4.4A protein at the invasive front acts as a novel prognostic marker in colorectal cancer, possibly through invasion-related mechanisms.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Female. GPI-Linked Proteins. HCT116 Cells. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Prognosis. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Cancer Association.
  • [ErratumIn] Cancer Sci. 2010 Nov;101(11):2503
  • (PMID = 20825414.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / LYPD3 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


31. Kinnier CV, Eu JP, Davis RD, Howell DN, Sheets J, Palmer SM: Successful bilateral lung transplantation for lymphangiomatosis. Am J Transplant; 2008 Sep;8(9):1946-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the first successful case of bilateral lung transplantation for the treatment of end-stage pulmonary lymphangiomatosis.
  • The primary obstacles to significant gains in pulmonary function were thoracic, skeletal and abdominal lymphangiomatosis, which led to pulmonary restriction.

  • Genetic Alliance. consumer health - Lymphangiomatosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2006 Oct;13(4):276-85 [17075565.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(6):407-11 [9498881.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1664-5 [17532983.001]
  • [Cites] Pediatr Hematol Oncol. 2007 Oct-Nov;24(7):513-24 [17786787.001]
  • [Cites] Liver Transpl. 2007 Nov;13(11):1593-7 [17969190.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):1037-46 [10712360.001]
  • [Cites] Pediatr Pulmonol. 2000 Apr;29(4):321-4 [10738021.001]
  • [Cites] Arch Dis Child. 2000 Aug;83(2):138-9 [10906021.001]
  • [Cites] J Heart Lung Transplant. 2004 Mar;23(3):301-8 [15019639.001]
  • [Cites] N Engl J Med. 1980 Jul 31;303(5):270-6 [7383110.001]
  • [Cites] Ann Thorac Surg. 1985 Oct;40(4):398-401 [4051622.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):329-35 [8494102.001]
  • [Cites] Hum Pathol. 1993 Dec;24(12):1313-22 [8276379.001]
  • [Cites] Radiology. 1995 Feb;194(2):343-7 [7529933.001]
  • [Cites] Histopathology. 1995 Nov;27(5):482-3 [8575743.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 May-Jun;19(3):232-6 [9201146.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1711-6 [9448622.001]
  • [Cites] Semin Respir Crit Care Med. 2007 Feb;28(1):134-40 [17330198.001]
  • (PMID = 18671675.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K23 HL069978; United States / NHLBI NIH HHS / HL / HL69978
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS498877; NLM/ PMC3732029
  •  go-up   go-down


32. Fang H, Wang XY, Wang JW, Zhang HG, Feng FY, Shi YK: [Analysis of prognostic factors in 300 colorectal cancer patients with liver metastases]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):220-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic factors in 300 colorectal cancer patients with liver metastases].
  • OBJECTIVE: To analyse the clinical characteristics and potential prognostic factors of colorectal cancer patients with liver metastases.
  • METHODS: The clinical and pathological data of 300 colorectal cancer patients with liver metastases were retrospectively reviewed and analyzed.
  • The 1-, 2- and 5-year survival rates after liver metastases were 79.0%, 29.0% and 3.0%, respectively.
  • Univariate analysis revealed that performance status (KPS), histological grading, primary tumor, N status, lymphatic and vascular invasion, stage at diagnosis, the number, size and distribution of liver metastases and other accompanied metastases were prognostic factors.
  • Multivariate analysis showed that KPS, lymphatic and vascular invasion, the number and size of liver metastases were independent prognostic factors of colorectal cancer with liver metastases.
  • CONCLUSION: Performance status, lymphatic and vascular invasion, the number and size of liver metastases are independent prognostic factors of colorectal cancer with liver metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615265.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Furuta K, Sato S, Yamauchi T, Ozawa T, Harada M, Kakumu S: Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease. J Gastroenterol; 2008;43(11):866-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease.
  • BACKGROUND: DNA microarray technology has enabled genomewide analysis of gene transcript levels, yielding insight into the molecular nature of liver disease.
  • METHODS: We compared gene expression of liver biopsy specimens in 16 patients with different stages of chronic hepatitis B, five with autoimmune hepatitis (AIH), five with primary biliary cirrhosis (PBC), and six with druginduced hepatitis.
  • Genes associated with extracellular matrix, cell growth, and DNA repair were noted in the advanced fibrotic stage of chronic hepatitis B (B-3), while gene expression regarding complement activation and the innate immune response decreased.
  • When we compared gene expression at the relatively early stage in each disease group with pathway analysis, pathways relating to chemotaxis and cell homeostasis were selected in chronic hepatitis B.
  • CONCLUSIONS: Analysis of gene expression in liver may be useful for understanding features of distinct liver diseases and for guiding disease progression, particularly in chronic hepatitis B.
  • [MeSH-minor] Adult. Biopsy. Disease Progression. Epithelial Cell Adhesion Molecule. Female. Gene Expression Profiling. Genetic Predisposition to Disease. Humans. Liver / metabolism. Liver / pathology. Lumican. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Autoimmune Hepatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Dec;129(6):2064-75 [16344072.001]
  • [Cites] N Engl J Med. 1993 Jun 24;328(25):1797-801 [7684822.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):929-38 [10580593.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1315-22 [10096565.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):53-61 [12853201.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Hepatology. 2004 Sep;40(3):667-76 [15349906.001]
  • [Cites] Hepatology. 2001 Dec;34(6):1225-41 [11732013.001]
  • [Cites] Hepatology. 2001 Apr;33(4):832-40 [11283847.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1122-38 [17058214.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):955-66 [11231949.001]
  • [Cites] Hepatol Res. 2007 Oct;37(10):820-7 [17517078.001]
  • [Cites] Hepatology. 2005 Aug;42(2):481-9 [16025496.001]
  • [Cites] Hepatology. 2003 Jan;37(1):198-207 [12500205.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):196-204 [8988900.001]
  • [Cites] Hepatology. 1994 Jun;19(6):1513-20 [8188183.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):443-7 [12504104.001]
  • [Cites] Hepatology. 2005 Aug;42(2):273-81 [15986378.001]
  • [Cites] Transl Res. 2006 Sep;148(3):103-13 [16938647.001]
  • [Cites] Clin Liver Dis. 2000 Feb;4(1):73-96, vi [11232192.001]
  • (PMID = 19012040.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / Chondroitin Sulfate Proteoglycans; 0 / EFEMP1 protein, human; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule; 0 / Extracellular Matrix Proteins; 0 / LUM protein, human; 0 / Lumican; 63231-63-0 / RNA; 9056-36-4 / Keratan Sulfate
  •  go-up   go-down


34. Hauschild A, Dummer R, Ugurel S, Kaehler KC, Egberts F, Fink W, Both-Skalsky J, Laetsch B, Schadendorf D: Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. Cancer; 2008 Sep 15;113(6):1404-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-eight patients with stage IV melanoma without brain metastases were treated with DTIC (at a dose of 850 mg/m(2) every 3 weeks) combined with weekly pegylated IFN-alpha-2a at a dose of 180 microg.
  • The primary study endpoint was objective response.
  • Six of 7 nonprogressive patients had either not received treatment or had not developed disease progression during adjuvant IFN treatment for stage II/III disease.
  • Few grade 3 toxicities and only 1 grade 4 toxicity were observed (according to National Cancer Institute Common Toxicity Criteria).
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Drug Carriers. Drug Therapy, Combination. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Recombinant Proteins. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18615619.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antiviral Agents; 0 / Drug Carriers; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


35. Lee WS, Yun HR, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh JW, Park YS, Kang WK: Treatment outcomes of hepatic and pulmonary metastases from colorectal carcinoma. J Gastroenterol Hepatol; 2008 Aug;23(8 Pt 2):e367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: The resection of synchronous or metachronous pulmonary and liver metastasis is an aggressive treatment option for patients with stage IV colorectal cancer and has been shown to yield acceptable long-term survival.
  • We reviewed our experience with colorectal cancer patients with both liver and lung resections to determine the efficacy of surgical resections.
  • METHODS: We performed a single institution, retrospective analysis of all patients who underwent surgical hepatic and pulmonary resection for metastatic colorectal cancer between 1995 and 2004.
  • RESULTS: A total of 32 patients underwent resection of both hepatic and pulmonary metastases secondary to colorectal cancer.
  • Neither the number of pulmonary lesions nor the time interval between the primary surgery and the metastasectomy had a significant impact on survival (P = 0.134).
  • CONCLUSION: An aggressive surgical treatment of selected colorectal cancer patients with lung and liver metastases resulted in prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086122.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


36. Tabata M, Kozuki T, Ueoka H, Kiura K, Harita S, Tada A, Shibayama T, Takigawa N, Yonei T, Gemba K, Segawa Y, Kishino D, Tada S, Hiraki S, Tanimoto M, Okayama Lung Cancer Study Group: A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemother Pharmacol; 2007 Jun;60(1):53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
  • PURPOSE: We conducted a phase I/II study of triplet chemotherapy consisting of cisplatin (CDDP), docetaxel (DCT) and gemcitabine (GEM) in patients with advanced non-small-cell lung cancer (NSCLC).
  • METHODS: Fifty-three untreated patients with stage IIIB or IV NSCLC were enrolled.
  • In the phase I portion, a dose escalation study of GEM with starting dose of 400 mg/m(2) was conducted and primary objective in the phase II portion was response rate.
  • RESULTS: The maximally tolerated dose (MTD) and recommended dose (RD) of GEM were determined as 800 mg/m(2) because grade 3 non-hematological toxicity (liver damage, diarrhea, and fatigue) developed in three of nine patients evaluated at that dose level.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / pharmacokinetics. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacokinetics. Dose-Response Relationship, Drug. Female. Humans. Leukopenia / chemically induced. Male. Metabolic Clearance Rate. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Neoplasm Staging. Pregnancy. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / pharmacokinetics. Treatment Outcome. Vomiting / chemically induced


37. Gervaz P, Rubbia-Brandt L, Andres A, Majno P, Roth A, Morel P, Mentha G: Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol; 2010 Oct;17(10):2714-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
  • BACKGROUND: We report the histopathological results of a novel "inversed" strategy designed to manage patients with colorectal cancer (CRC) who have synchronous liver metastases by using chemotherapy first, liver surgery second, and resection of the primary tumor as a final step.
  • This study was designed to compare the response to chemotherapy in liver metastases, primary tumors, and locoregional lymph nodes.
  • METHODS: Twenty-nine patients with stage IV CRC received a combination of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (OCFL) for 3-4 months.
  • Primary tumor location was right colon (n = 5), left colon (n = 7), and rectum (n = 17 patients).
  • TRG scores correlated across disease sites (Spearman correlation coefficients for TRG in the primary tumor and lymph nodes was 0.59 [P = 0.005]; for the primary tumor and metastases 0.44 [P = 0.021]; and for lymph nodes and metastases 0.58 [P = 0.006]).
  • Complete absence or poor tumor response (TRG4/5) was significantly more frequent in primary tumors (35.7%) and locoregional lymph nodes (38%) than in liver metastases (6.9%; McNemar test, P = 0.02).
  • CONCLUSIONS: In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lymph Nodes / drug effects. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405223.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


38. Yinglu F, Changquan L, Xiaofeng Z, Bai L, Dezeng Z, Zhe C: A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization. J Altern Complement Med; 2009 Feb;15(2):175-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In the randomized, double-blinded and controlled trial, 120 patients with primary liver cancer were divided into 4 groups, with 30 patients in each group.
  • RESULTS: The results indicated that Dex combined with GS not only markedly decreased the occurrence ratio and duration of such symptoms as nausea, vomiting, and fever, but also significantly reduced levels of total bilirubin, glutamic oxaloacetic transaminase, and glutamic-pyruvic transaminase (AST) and improved the Child-Pugh stage of liver function as compared with single use of GS or Dex.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chemoembolization, Therapeutic / adverse effects. Dexamethasone / therapeutic use. Ginsenosides / therapeutic use. Liver Neoplasms / drug therapy. Panax / chemistry. Plant Extracts / therapeutic use
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Bilirubin / blood. Combined Modality Therapy. Double-Blind Method. Drug Therapy, Combination. Female. Fever / drug therapy. Fever / etiology. Humans. Male. Middle Aged. Nausea / drug therapy. Nausea / etiology. Phytotherapy. Vomiting / drug therapy. Vomiting / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216654.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ginsenosides; 0 / Plant Extracts; 7S5I7G3JQL / Dexamethasone; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


39. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol; 2005 Apr 20;23(12):2744-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
  • PURPOSE: Liver metastasis is the predominant cause of colorectal cancer (CRC) related mortality.
  • Chemokines, soluble factors that orchestrate hematopoetic cell movement, have been implicated in directing cancer metastasis, although their clinical relevance in CRC has not been defined.
  • METHODS: CRC cell lines (n = 6) and tumor specimens (n = 139) from patients with different American Joint Committee on Cancer (AJCC) stages of CRC were assessed.
  • RESULTS: High CXCR4 expression in tumor specimens (n = 57) from AJCC stage I/II patients was associated with increased risk for local recurrence and/or distant metastasis (risk ratio, 1.35; 95% CI, 1.09 to 1.68; P = .0065).
  • High CXCR4 expression in primary tumor specimens (n = 35) from AJCC stage IV patients correlated with worse overall median survival (9 months v 23 months; RR, 2.53; 95% CI, 1.19 to 5.40; P = .016).
  • CXCR4 expression was significantly higher in liver metastases (n = 39) compared with primary CRC tumors (n = 100; P < .0001).
  • CXCR4 gene expression in primary CRC demonstrated significant associations with recurrence, survival, and liver metastasis.
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Gene Expression Profiling. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / genetics. Receptors, CXCR4 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / physiopathology. Prognosis. Risk Factors. Signal Transduction. Survival Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837989.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA90848-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CXCR4
  •  go-up   go-down


40. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol; 2006 Oct;45(4):529-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
  • BACKGROUND/AIMS: End-stage liver disease accounts for one in forty deaths worldwide.
  • Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are well-recognized risk factors for cirrhosis and liver cancer, but estimates of their contributions to worldwide disease burden have been lacking.
  • Applied to 2002 worldwide mortality estimates, these fractions represent 929,000 deaths due to chronic HBV and HCV infections, including 446,000 cirrhosis deaths (HBV: n=235,000; HCV: n=211,000) and 483,000 liver cancer deaths (HBV: n=328,000; HCV: n=155,000).
  • CONCLUSIONS: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
  • [MeSH-major] Global Health. Hepatitis B, Chronic / mortality. Hepatitis C, Chronic / mortality. Liver Cirrhosis / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. World Health Organization


41. Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, Del Mastro L: Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat; 2006 Jan;95(1):45-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
  • The primary objective of study is to evaluate cardiac safety of trastuzumab in combination with epirubicin and docetaxel.
  • HER2-overexpressing metastatic breast cancer patients were enrolled in a two-stage, multicenter phase II trial with weekly trastuzumab (4 and then 2 mg/kg) with epirubicin and docetaxel (either 75 mg/m(2)) on day 1 every 3 weeks.
  • In the first stage of the study, three episodes of cardiotoxicity were observed (two asymptomatic declines of LVEF and one CHF) in 29 patients, and recruitment continued.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Epirubicin / administration & dosage. Female. Humans. Lymphatic Metastasis / pathology. Lymphatic Metastasis / prevention & control. Middle Aged. Taxoids / administration & dosage. Trastuzumab


42. Kocic B, Filipovic S, Petrovic B, Mijalkovic D, Rancic N, Poultsidi A: Clinical and biological characteristics of breast cancer. J BUON; 2010 Oct-Dec;15(4):660-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological characteristics of breast cancer.
  • PURPOSE: in view of the crucial importance of early detection and diagnosis of breast cancer for subsequent treatment and prognosis, the aim of this study was to identify clinical and biological characteristics of breast cancer at the time of diagnosis.
  • METHODS: the study enrolled 449 breast cancer patients in Clinical Centre Nis.
  • TNM clinical stage IIA was identified in 27.6% of the patients, T2 in 49.2% and Tis in 0.9%.
  • Most common monolocalization of metastatic disease was the liver and the supraclavicular lymph nodes, and combined localization was the liver and bones.
  • The most common primary tumor site was the upper lateral quadrant.
  • CONCLUSION: in view of the unfavorable age of patients at the time of diagnosis and clinical and biological tumor characteristics, the results confirmed that it is of vital importance to provide breast cancer prevention, screening, and to organize breast cancer units according EUSOMA guidelines.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Female. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Young Adult


43. Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG: Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res; 2005 Feb;15(1):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.
  • Melanoma may present metastatically without an identifiable primary lesion.
  • To further characterize the epidemiology of melanoma of unknown primary (MUP), we report our experience with a cohort of MUP patients.
  • We retrospectively reviewed patients seen at the Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI) between 1986 and 1996 with follow-up to 2002.
  • After adjusting for stage and age at diagnosis, there was some evidence that men survived longer than women [hazard ratio (HR)=0.55; 95% CI, 0.28, 1.09].
  • [MeSH-major] Melanoma / epidemiology. Neoplasms, Unknown Primary / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Boston / epidemiology. Brain Neoplasms / secondary. Cohort Studies. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714125.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


44. Lathrop MJ, Hsu M, Richardson CA, Olivier EN, Qiu C, Bouhassira EE, Fiering S, Lowrey CH: Developmentally regulated extended domains of DNA hypomethylation encompass highly transcribed genes of the human beta-globin locus. Exp Hematol; 2009 Jul;37(7):807-813.e2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Bisulfite sequencing was used to determine the methylation state of individual CpG dinucleotides across the beta-globin locus in uncultured primary human erythroblasts from fetal liver and bone marrow, and in primitive-like erythroid cells derived from human embryonic stem cells.
  • RESULTS: beta-globin locus CpGs are generally highly methylated, but domains of DNA hypomethylation spanning thousands of base pairs are established around the most highly expressed genes during each developmental stage.
  • We also find hypomethylation of a small proportion of gamma-globin promoters in adult erythroid cells, suggesting a mechanism by which adult erythroid cells produce fetal hemoglobin.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6617-22 [16608912.001]
  • [Cites] N Engl J Med. 1993 Sep 16;329(12):845-8 [7689171.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:58-62 [17124041.001]
  • [Cites] PLoS One. 2006;1:e46 [17183675.001]
  • [Cites] Nucleic Acids Res. 2007;35(3):801-11 [17202157.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Am J Hematol. 1994 Jul;46(3):169-72 [8192145.001]
  • [Cites] Blood Rev. 1994 Dec;8(4):213-24 [7534152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13724-9 [9391093.001]
  • [Cites] Genes Dev. 1999 Oct 1;13(19):2465-77 [10521391.001]
  • [Cites] Nat Struct Mol Biol. 2004 Nov;11(11):1068-75 [15467727.001]
  • [Cites] Exp Hematol. 2005 Mar;33(3):259-71 [15730849.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R41-6 [15809272.001]
  • [Cites] Exp Hematol. 2005 Dec;33(12):1450-8 [16338487.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1412-7 [16432200.001]
  • [Cites] Trends Biochem Sci. 2006 Feb;31(2):89-97 [16403636.001]
  • [Cites] Curr Opin Cell Biol. 2007 Jun;19(3):273-80 [17466503.001]
  • [Cites] Mol Cell Biol. 2007 Jul;27(13):5047-54 [17452448.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1343-52 [17456718.001]
  • [Cites] Am J Hematol. 2007 Nov;82(11):981-5 [17696208.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3391-7 [17638855.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4101-7 [17881636.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2434-42 [17893234.001]
  • [Cites] Blood. 2008 Jan 1;111(1):411-20 [17916742.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2400-8 [18024790.001]
  • [Cites] Curr Top Dev Biol. 2008;82:85-116 [18282518.001]
  • [Cites] Nature. 2008 Aug 7;454(7205):766-70 [18600261.001]
  • [Cites] Cell. 1999 Nov 24;99(5):451-4 [10589672.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):377-86 [10882078.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):1897-905 [11684679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5 [11891299.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Immunity. 2002 May;16(5):649-60 [12049717.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6694-702 [12242669.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4158-66 [12874021.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3865-70 [12907443.001]
  • [Cites] EMBO J. 2003 Dec 1;22(23):6335-45 [14633992.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1531-8 [14716296.001]
  • [Cites] Am J Hum Genet. 1973 May;25(3):271-6 [4735813.001]
  • [Cites] Science. 1975 Apr 25;188(4186):361-3 [804182.001]
  • [Cites] Blood. 1975 Nov;46(5):671-82 [1100141.001]
  • [Cites] Cell. 1980 Apr;19(4):947-58 [6247075.001]
  • [Cites] N Engl J Med. 1982 Dec 9;307(24):1469-75 [6183586.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Nov;80(22):6907-11 [6316333.001]
  • [Cites] Prog Clin Biol Res. 1983;134:421-30 [6198658.001]
  • [Cites] Prog Clin Biol Res. 1983;134:457-74 [6198660.001]
  • [Cites] Prog Clin Biol Res. 1983;134:475-88 [6198661.001]
  • [Cites] EMBO J. 1992 Jan;11(1):327-33 [1310933.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3272-81 [7684493.001]
  • [Cites] J Hum Genet. 2006;51(5):440-50 [16544050.001]
  • (PMID = 19460471.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL073431; United States / NHLBI NIH HHS / HL / R01 HL088467; United States / NCRR NIH HHS / RR / P20 RR016437; United States / NIDDK NIH HHS / DK / R01 DK054071; United States / NHLBI NIH HHS / HL / HL088467; United States / NHLBI NIH HHS / HL / R01 HL073442; United States / NCI NIH HHS / CA / P30 CA023108; United States / NIGMS NIH HHS / GM / P20 GM075037; United States / NIAID NIH HHS / AI / T32 AI07363; United States / NHLBI NIH HHS / HL / HL73431; United States / NIGMS NIH HHS / GM / GM075037; United States / NHLBI NIH HHS / HL / HL73442; United States / NIAID NIH HHS / AI / T32 AI007363
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / beta-Globins
  • [Other-IDs] NLM/ NIHMS128449; NLM/ PMC3792488
  •  go-up   go-down


45. Pelli N, Floreani A, Torre F, Delfino A, Baragiotta A, Contini P, Basso M, Picciotto A: Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. Clin Exp Immunol; 2007 Apr;148(1):85-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.
  • Apoptosis in the liver is generated mainly by the Fas system.
  • In the liver environment hepatocytes and biliary epithelial cells express TRAIL receptors which are up-regulated by increased levels of bile acids and during viral hepatitis.
  • To explore the commitment and level of activation of these two apoptotic systems in patients affected by primary biliary cirrhosis (PBC) or chronic hepatitis C (CH-C), a comparative study was drawn.
  • No correlation between sFasL and sTRAIL, stage of disease, liver histology in each disease and cytolysis was present.
  • [MeSH-major] Fas Ligand Protein / blood. Hepatitis C, Chronic / immunology. Liver Cirrhosis, Biliary / immunology. TNF-Related Apoptosis-Inducing Ligand / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Enzyme-Linked Immunosorbent Assay / methods. Female. Hepatocytes / pathology. Humans. Male. Middle Aged. Solubility

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1997 Dec;26(6):1399-405 [9397977.001]
  • [Cites] Science. 1997 Aug 8;277(5327):818-21 [9242611.001]
  • [Cites] J Clin Invest. 1998 Jun 15;101(12):2790-9 [9637713.001]
  • [Cites] Liver. 1998 Aug;18(4):277-84 [9766825.001]
  • [Cites] J Clin Invest. 1999 Jan;103(1):137-45 [9884343.001]
  • [Cites] J Immunol. 1999 Jul 15;163(2):920-6 [10395688.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8502-6 [15574753.001]
  • [Cites] Ann Clin Lab Sci. 2004 Autumn;34(4):400-4 [15648780.001]
  • [Cites] Clin Chim Acta. 2006 Mar;365(1-2):113-8 [16139828.001]
  • [Cites] J Interferon Cytokine Res. 2006 Feb;26(2):119-23 [16487032.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2000 Feb;22(1):19-33 [10737254.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3328-9 [11095382.001]
  • [Cites] Liver. 2001 Aug;21(4):272-9 [11454191.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4881-8 [11994437.001]
  • [Cites] Liver. 2002 Jun;22(3):228-34 [12100573.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Nov;303(2):461-7 [12388624.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1077-80 [12439929.001]
  • [Cites] FASEB J. 2003 Jan;17(1):94-6 [12475902.001]
  • [Cites] J Hepatol. 2003 Sep;39(3):414-20 [12927928.001]
  • [Cites] J Viral Hepat. 2003 Sep;10(5):335-42 [12969183.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):51-60 [14561739.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):58-64 [14702109.001]
  • [Cites] Hepatology. 2004 Feb;39(2):273-8 [14767974.001]
  • [Cites] Liver Int. 2004 Apr;24(2):85-9 [15078470.001]
  • [Cites] J Histochem Cytochem. 2004 Jun;52(6):821-31 [15150291.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] Hepatology. 1997 May;25(5):1077-84 [9141420.001]
  • [Cites] Nat Med. 1998 Jan;4(1):21-2 [9427600.001]
  • (PMID = 17302732.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fas Ligand Protein; 0 / TNF-Related Apoptosis-Inducing Ligand
  • [Other-IDs] NLM/ PMC1868846
  •  go-up   go-down


46. Alwan M, Stubbs R: Local recurrence in patients with synchronous or metachronous colorectal liver metastases--is there a difference? N Z Med J; 2005 Aug 26;118(1221):U1631
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence in patients with synchronous or metachronous colorectal liver metastases--is there a difference?
  • AIM: To determine whether the seemingly high rate of local recurrence after colorectal cancer surgery in the presence of liver metastases results from factors related to the surgical excision of the primary tumour or greater biological aggressiveness of the tumour.
  • METHODS: A retrospective study comparing local recurrence rates and surgical and pathological variables noted in operation and pathology reports was undertaken in 65 patients being treated for synchronous liver metastases (Group 1), and 42 patients being treated for metachronous liver metastases (Group 2).
  • The local recurrence after rectal cancer excision in the two groups was 27.3% and 12.5% respectively (p=0.28).
  • Neither was there any significant difference between the tumour grade, stage, or venous invasion.
  • CONCLUSIONS: Although a high local recurrence rate was found in Group 1 in particular, there is no evidence that this relates to the extent of resection at the time of primary tumour removal.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Colon / pathology. Colon / surgery. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. New Zealand / epidemiology. Rectum / pathology. Rectum / surgery. Retrospective Studies. Risk Factors. Tumor Burden

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16138169.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


47. Garioud A, Seksik P, Chrétien Y, Corphechot C, Poupon R, Poupon RE, Chazouillères O: Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol; 2010 Jul;22(7):842-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) is a rare disease, and large-scale report of PSC in France is lacking.
  • At entry, 11 patients had a diagnosis of hepatobiliary or colon malignancy (cholangiocarcinoma: n = 5, hepatocellular carcinoma: n = 2, gallbladder carcinoma: n = 1 and colorectal cancer: n = 4).
  • RESULTS: During follow-up [3.9 (0.1-7.2) years], colorectal cancer was diagnosed in four patients and biliary carcinoma in two (incidences: 0.76 and 0.38 for 100 patient-years, respectively).
  • Main causes of death (n = 10) were cancer (n = 5, including three colorectal cancers and two cholangiocarcinoma) or liver failure (n = 4).
  • Indications for transplantation (n = 25) were end-stage liver disease (n = 16), biliary cancer (known or suspected) (n = 5), recurrent acute cholangitis (n = 3) or pruritus (n = 1).
  • [MeSH-major] Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / mortality. Liver Failure / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic / drug effects. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / drug therapy. Cohort Studies. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Female. France / epidemiology. Gallbladder Neoplasms / diagnosis. Gallbladder Neoplasms / drug therapy. Humans. Incidence. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Transplantation. Male. Middle Aged. Prognosis. Prospective Studies. Treatment Outcome. Ursodeoxycholic Acid / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779305.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


48. Abraham SC, Poterucha JJ, Rosen CB, Demetris AJ, Krasinskas AM: Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol; 2008 Jul;32(7):965-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests.
  • The utility of protocol liver allograft biopsies remains controversial, particularly in patients with normal liver function tests (LFTs).
  • However, histologic evaluation of these biopsies provides an opportunity to examine the types and severity of liver diseases that can occur in livers with normal clinical and biochemical function.
  • We studied 165 protocol allograft biopsies taken from 100 liver transplant patients at the time of normal LFTs and normal clinical function at 3 to 8 months (n=36), 1 year (n=52), 2 to 3 years (n=54), and 4 to 5 years (n=23).
  • Biopsies were classified as normal, minimal changes (eg, nonaggressive portal or lobular mononuclear inflammation, steatosis <10%), fatty liver disease, recurrent primary liver disease, and transplant-related disease (portal-based rejection or central venulitis, an inflammatory pattern that encompasses perivenular hepatocyte dropout, mononuclear inflammation, pigment-laden macrophages, and variable zone 3 fibrosis).
  • Forty-four (27%) showed histologic abnormalities that included fatty liver disease (n=19, nonalcoholic in 18 cases; 13 with mild steatosis, 6 with moderate steatosis, 7 with grade 1/3 steatohepatitic activity, and 2 with stage 1/4 steatohepatitic fibrosis), recurrent primary biliary cirrhosis (n=9; all stage 1/4), recurrent hepatitis C infection (n=6; grade 0/4 in 1, grade 1/4 in 5, stage 0/4 in 4, stage 1/4 in 1, and stage 2/4 in 1), recurrent sarcoidosis (n=1), Ito cell hyperplasia (n=4; marked in 2 and mild in 2), central venulitis (n=10; 5 with mild zone 3 fibrosis or central vein obliteration and 1 with central-portal bridging fibrosis), and mild acute portal rejection (n=2).
  • These most commonly include fatty liver disease, low-grade/low-stage recurrent hepatitis C and primary biliary cirrhosis, and central venulitis (including some cases with subsequent fibrosis progression).
  • The data support performance of protocol biopsies to assess allograft status, and provide insight into the types and severity of liver diseases that can smolder in transplanted (and by extension, probably also in native) livers with apparent normal function.
  • [MeSH-major] Liver Diseases / diagnosis. Liver Transplantation / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Child. Child, Preschool. Clinical Protocols. Fatty Liver / diagnosis. Fatty Liver / physiopathology. Female. Hepatitis C, Chronic / diagnosis. Hepatitis C, Chronic / physiopathology. Humans. Infant. Liver Cirrhosis, Biliary / diagnosis. Liver Cirrhosis, Biliary / physiopathology. Liver Function Tests. Male. Middle Aged. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460980.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH: Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol; 2010 Aug;66(3):507-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
  • PURPOSE: The primary aim of this study was to compare the relapse patterns of estrogen receptor (ER)-positive and ER-negative patients with HER2-overexpressing breast cancer.
  • A secondary aim was to distinguish the preferential primary site of metastases in HER2-overexpressing breast cancer.
  • METHODS: Out of 886 patients treated for metastatic breast cancer (MBC) between January 1995 and December 2006, 269 patients with HER2-positive tumors were identified.
  • Of these, 198 patients with relapsed breast cancer following surgery were included in this study.
  • Young age [hazard ratio (HR) 1.59, p = 0.002], TNM stage 3 (HR 1.51, p = 0.005), and ER-negativity (HR 1.68, p < 0.0001) were identified as independent risk factors for relapse.
  • CONCLUSIONS: Our study shows that HER2-overexpressing breast cancer displays characteristic patterns of relapse and metastatic spread depending on ER status.
  • [MeSH-minor] Adult. Age Factors. Aged. Bone Neoplasms / secondary. Cross-Sectional Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Risk Factors. Severity of Illness Index. Time Factors


50. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA; 2008 Nov;14(11):2348-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
  • To investigate the global expression profile of miRNAs in primary breast cancer (BC) and normal adjacent tumor tissues (NATs) and its potential relevance to clinicopathological characteristics and patient survival, the genome-wide expression profiling of miRNAs in BC was investigated using a microarray containing 435 mature human miRNA oligonucleotide probes.
  • Interestingly, among the 113 BC cases, high level expression of miR-21 was significantly correlated with advanced clinical stage (P = 0.006, Fisher's exact text), lymph node metastasis (P = 0.007, Fisher's exact text), and shortened survival of the patients (hazard ratio [HR]=5.476, P < 0.001).
  • Multivariate Cox regression analysis revealed this prognostic impact (HR=4.133, P = 0.001) to be independent of disease stage (HR=2.226, P = 0.013) and histological grade (HR=3.681, P = 0.033).
  • This study could identify the differentiated miRNAs expression profile in BC and reveal that miR-21 overexpression was correlated with specific breast cancer biopathologic features, such as advanced tumor stage, lymph node metastasis, and poor survival of the patients, indicating that miR-21 may serve as a molecular prognostic marker for BC and disease progression.
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Mar;18(3):350-9 [18270520.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Treat Rev. 2001 Jun;27(3):137-42 [11417963.001]
  • [Cites] Bioinformatics. 2001;17 Suppl 1:S49-55 [11472992.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):408-17 [12219783.001]
  • [Cites] Lancet. 2003 Mar 15;361(9361):923-9 [12648972.001]
  • [Cites] Cell. 2003 Jun 13;113(6):673-6 [12809598.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer. 2005 May 1;103(9):1770-7 [15770691.001]
  • [Cites] Nat Methods. 2004 Oct;1(1):47-53 [15782152.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):155-61 [15782179.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] Nat Med. 2005 Jul;11(7):712-4 [16015356.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] RNA. 2006 May;12(5):913-20 [16540696.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4677-84 [16966691.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):438-40 [17152490.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6092-9 [17616664.001]
  • [Cites] BMC Biotechnol. 2007;7:36 [17603869.001]
  • (PMID = 18812439.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN21 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2578865
  •  go-up   go-down


51. Moghimi-Dehkordi B, Safaee A, Ghiasi S, Zali MR: Survival in gastric cancer patients: univariate and multivariate analysis. East Afr J Public Health; 2009 Apr;6 Suppl(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in gastric cancer patients: univariate and multivariate analysis.
  • BACKGROUND AND AIM: Cancer for a long time has been recognized as a fatal disease.
  • In recent years, cancer morbidity and mortality increased in our country and especially gastric cancer has second order among all cancers.
  • The aim of this study was to analysis the survival of patients diagnosed with gastric cancer and the factors which modify prognosis.
  • METHODS: Retrospective study of overall patients diagnosed with gastric cancer registered in the cancer registry center of Research Center for Gastroenterology and Liver Disease (RCGLD), Shahid Beheshti University, M.C, Tehran, Iran, between Dec.
  • With univariate analysis, Age at Diagnosis, surgery treatment, type of first treatment, pathologic stage, tumor size, histology type of tumor, extent of wall penetration and pathologic distant metastasis were significant prognostic factors related to overall survival time.
  • CONCLUSIONS: According to results, early detection of cancer in lower ages and in primary grades of tumor is important to increase patient's life expectancy.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Iran / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084985.001).
  • [ISSN] 0856-8960
  • [Journal-full-title] East African journal of public health
  • [ISO-abbreviation] East Afr J Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tanzania
  •  go-up   go-down


52. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM, HCC Italian Task Force: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology; 2006 Dec;44(6):1543-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
  • A predetermined group of 150 HCV RNA-positive patients undergoing resection of early- to intermediate-stage HCC was stratified into 80 HCV-pure (hepatitis B anticore antibody [anti-HBc]-negative) and 70 mixed HCV+hepatitis B virus (HBV) (anti-HBc-positive) groups, then randomized to IFN-alpha (3 million units 3 times every week for 48 weeks [n = 76]) versus control (n = 74).
  • The primary end point was recurrence-free survival (RFS); secondary end points were disease-specific and overall survival.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Liver Cirrhosis / drug therapy. Liver Neoplasms / prevention & control. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Aged. Comorbidity. Female. Hepatectomy. Hepatitis B Core Antigens / analysis. Hepatitis B, Chronic / complications. Humans. Male. Middle Aged. Multivariate Analysis. Recombinant Proteins. Risk. alpha-Fetoproteins / analysis


53. Yedibela S, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos T, Göhl J, Hohenberger W: Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol; 2006 Nov;13(11):1538-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of pulmonary metastases from colorectal cancer in 153 patients.
  • METHODS: A retrospective analysis of the records of all patients (n = 153) with pulmonary metastases from colorectal cancer who underwent thoracotomy between 1978 and 2003 at a single surgical center was performed.
  • RESULTS: One hundred fifty-three patients with pulmonary metastases from colon (n = 61) or rectal (n = 92) cancer underwent 180 thoracotomies.
  • Sex, age, site, International Union Against Cancer stage of the primary tumor, prethoracotomy carcinoembryonic antigen level, size of metastases, and previous resection of hepatic metastases were not found to be statistically significant prognostic factors.
  • CONCLUSIONS: Pulmonary resection for metastases from colorectal cancer is safe and results in long-term survival in selected patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / metabolism. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Node Excision. Lymphatic Metastasis. Male. Medical Records. Middle Aged. Retrospective Studies. Survival Rate. Thoracotomy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009154.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


54. Tanioka M, Katsumata N, Sasajima Y, Ikeda S, Kato T, Onda T, Kasamatsu T, Fujiwara Y: Clinical characteristics and outcomes of women with stage IV endometrial cancer. Med Oncol; 2010 Dec;27(4):1371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcomes of women with stage IV endometrial cancer.
  • Treatment strategies for patients with stage IV endometrial cancer (EC) remain controversial.
  • We retrospectively analyzed the clinical characteristics and outcomes of 41 women with stage IV EC.
  • The results of preoperative cytologic evaluation and biopsy of the endometrium were reviewed by a single pathologist for patients in whom stage IV EC was diagnosed preoperatively.
  • Of the 41 patients with stage IV EC (median age, 62 years), 31 had surgical stage IV disease and 10 had clinical stage IV disease.
  • Twenty-eight patients were diagnosed of stage IV EC before surgery or without surgery.
  • Neither surgery as primary therapy nor optimal cytoreduction was significantly related to overall survival in either the 28 patients in whom stage IV was diagnosed preoperatively or in all 41 patients.
  • In women with stage IV EC, histologic features and extent of disease are more important determinants of outcomes than any kind of treatment.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):4-9 [14751130.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):85-91 [10926785.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):285-91 [17688923.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):56-60 [9345357.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):448-53 [12366661.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):325-33 [17532033.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):10-4 [14751131.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):133-8 [15385122.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):345-52 [15099944.001]
  • (PMID = 20024630.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Aletti GD, Dowdy SC, Podratz KC, Cliby WA: Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol; 2007 Apr;105(1):84-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system.
  • OBJECTIVES: Determine impact of tumor distribution and surgery on prognosis in patients with stage IV epithelial ovarian cancer (EOC).
  • METHODS: Retrospective analysis of stage IV EOC patients undergoing primary surgery between 1994 and 1998.
  • A very high risk group of patients based on extent of peritoneal disease, parenchymal liver metastases and ASA could be identified in whom the rate of optimal debulking was less than 25% (median survival 1.4 years).
  • No patients with multiple liver metastases were optimally cytoreduced and the median survival was 1 year.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate


56. Shen XY, Chai CH, Xiao WB, Wang QD: Diagnostic value of the fluoroscopic triggering 3D LAVA technique for primary liver cancer. Hepatobiliary Pancreat Dis Int; 2010 Apr;9(2):159-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of the fluoroscopic triggering 3D LAVA technique for primary liver cancer.
  • BACKGROUND: Primary liver cancer (PLC) is one of the common malignant tumors.
  • Liver acquisition with acceleration volume acquisition (LAVA), which allows simultaneous dynamic enhancement of the hepatic parenchyma and vasculature imaging, is of great help in the diagnosis of PLC.
  • This study aimed to evaluate application of the fluoroscopic triggering 3D LAVA technique in the imaging of PLC and liver vasculature.
  • RESULTS: Thirty-eight patients gave high quality images of 72 nodules in the liver for diagnosis.
  • Furthermore, small early-stage enhancing hepatic lesions and the parallel portal vein were also well displayed.
  • [MeSH-major] Fluoroscopy / methods. Imaging, Three-Dimensional / methods. Liver / pathology. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Hepatic Artery / pathology. Humans. Male. Middle Aged. Portal Vein / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382587.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


57. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • METHODS: Tumor registry data were collected between 1994-1996 on 11 primary tumor sites and 15 metastatic sites from 4399 patients.
  • The primary and metastatic sites were cross-tabulated in various ways to identify patterns, and the authors developed algorithms by using multinomial logistic regression analysis to predict the locations of primary tumors based on metastatic patterns.
  • RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%).
  • The liver was the dominant metastatic site for gastrointestinal (GI) primary tumors (71% of patients), whereas bone and lung metastases were noted most frequently in non-GI primary tumors (43% and 29%, respectively).
  • In a study of combinations of liver, abdominal cavity, and bone metastases, 86% of prostate primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases.
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Wang Y, Xue F, Broaddus RR, Tao X, Xie SS, Zhu Y: Clinicopathological features in endometrial carcinoma associated with Lynch syndrome in China. Int J Gynecol Cancer; 2009 May;19(4):651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-seven patients who fulfilled Amsterdam criteria II were classified as having Lynch syndrome-associated endometrial carcinoma (group A), and 331 patients without a family history of cancer were classified as having sporadic endometrial carcinoma (group B).
  • RESULTS: There were 81 malignancies in 27 families with Lynch syndrome-associated endometrial carcinoma, including colorectal cancer (24.7%), endometrial carcinoma (21.0%), and liver (12.3%), stomach (9.9%), lung (6.2%), and breast (6.2%) cancers.
  • Second primary cancers occurred in 33.3% of patients in group A and 5.1% in group B (P = 0.000).
  • The most common second primary cancers were colorectal cancer (44%) and ovarian cancer (22%).
  • There was no difference between the 2 groups in incidence of diabetes mellitus or hypertension or in histological type and International Federation of Gynecology and Obstetrics stage.
  • CONCLUSIONS: Some clinicopathological features of Lynch syndrome-associated endometrial carcinoma, such as early onset and multiple primary carcinomas are similar in the Chinese and American/European populations.
  • However, the Chinese population had a unique family cancer distribution that included lung and breast cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. China. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / pathology. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Lynch syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509565.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol; 2009 Jul 1;27(19):3126-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
  • The primary end point was progression-free rate at 12 weeks (PFR(12 weeks)).
  • A Simon two-stage design was applied (P1 = 40%; P0 = 20%; alpha = beta = .1) for each stratum.
  • The adipocytic STS stratum was closed after the first stage, given insufficient activity (PFR(12 weeks), five [26%] of19).
  • Compared with historical controls who were treated with second-line chemotherapy, progression-free and overall survivals were prolonged in the three cohorts in which the primary end point was reached.
  • Other toxicities included liver enzyme elevations, myelosuppression, and proteinuria, all of which were mostly grades 1 to 2.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality


60. Morshed K, Szymański M, Siwiec H, Gołabek W: Laryngeal cancer in farmers from Lublin region of Poland. Ann Agric Environ Med; 2008;15(1):13-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal cancer in farmers from Lublin region of Poland.
  • The aim of the study was to analyse if work related risk factor had any influence on stage, localisation and histology of type of malignant tumour.
  • The group included 148 patients with primary laryngeal squamous cell carcinoma (LSCC) diagnosed and treated in our institution in the years 1999-2002.
  • The univariate analysis of demographical and clinicopathological features of the farmers' group versus the other professions group with LSCC showed a statistical significance for sex, age and G stage.
  • Nearly statistical significance was observed for the N stage (p=0.06) and for primary localisation of the tumour (p=0.05).
  • Distant metastases were observed in 7 (8.3%) of 84 farmers with LSCC, 6 to the lungs and one to the liver.
  • Farmers with larynx cancer had different presentation pattern than other profession patients.
  • The incidence of glottic cancer and well differentiated cancer was higher in farmers than in other professions.
  • The prevalence of larynx cancer in women was significantly lower among farmers than in other professions.
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Poland / epidemiology. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581974.001).
  • [ISSN] 1232-1966
  • [Journal-full-title] Annals of agricultural and environmental medicine : AAEM
  • [ISO-abbreviation] Ann Agric Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


61. Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long Z, Zhu H, Wang Y: Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol; 2010 Sep 1;102(3):249-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: There were no comprehensive studies on the clinicopathologic features and prognosis of alpha-protein-producing gastric cancer.
  • The aim of this study was to elucidate the clinicopathologic characteristics and prognostic factors of alpha-fetoprotein (AFP)-producing gastric cancer.
  • METHODS: Among 4,426 gastric cancer patients receiving surgery in the Cancer Hospital of Fudan University from 1996 to 2007, there were 111 patients with elevated serum level of AFP preoperatively after excluding chronic hepatitis, hepatocirrhosis, and hepatocellular carcinoma.
  • Primary lesions of 104 patients were stained positively for AFP.
  • The clinicopathologic characteristics and prognostic factors of AFP-producing gastric cancer were analyzed.
  • Additionally, 208 stage-matched AFP-negative gastric cancer patients were selected as control.
  • RESULTS: There was a significantly higher incidence of vascular invasion, lymph node metastasis, and liver metastasis in AFP-positive group than in the negative group.
  • The AFP-positive group had a significantly poorer survival in comparison to the stage-matched negative group.
  • The independent prognostic factors of AFP-positive group included liver metastasis and pathological stage.
  • CONCLUSIONS: AFP-positive gastric cancer had more aggressive behavior than that of AFP-negative gastric cancer.
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Male. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20740583.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


62. Tao L, Yang JK: [Univariate analysis of syndrome differentiation in traditional Chinese medicine and clinical correlative factors in gastric cancer]. Zhong Xi Yi Jie He Xue Bao; 2007 Jul;5(4):398-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Univariate analysis of syndrome differentiation in traditional Chinese medicine and clinical correlative factors in gastric cancer].
  • OBJECTIVE: The research is aimed at investigating the developing rule and the relationship between syndrome differentiation in traditional Chinese medicine (TCM) and clinical factors of gastric cancer, so that it can be helpful to the clinical work and indicating the prognosis.
  • METHODS: We collected the medical records and the information of four diagnostic methods of 325 cases of gastric cancer sufferers in the way of clinical epidemiological survey, and divided them into 6 syndromes including dysfunction of spleen, disharmony of liver and stomach, blood stagnation in stomach, yin deficiency of stomach, phlegm dampness stagnation and deficiency of both qi and blood.
  • Then we used univariate analysis of variance, rank sum test and chi square test to analyse the relationship between syndrome differentiation and clinical-related factors such as age, gender, Karnofsky score and clinical stage, etc.
  • RESULTS: The syndrome of dysfunction of spleen plays the primary role in the disease.
  • Disharmony of liver and stomach always happens in early stage of stomach cancer, usually more often in radical operation cases and less in metastasis ones.
  • Phlegm dampness stagnation and blood stagnation in stomach usually can be seen in middle or advanced stage of the disease, which have lower Karnofsky score.
  • Deficiency of both qi and blood is the syndrome of stomach cancer in advanced stage, which results in lower living quality, and with high rate of relapse and metastasis.
  • Syndrome of yin deficiency of stomach has lower proportion in stomach cancer cases, and the clinical-related factors have low influence on it.
  • CONCLUSION: Syndrome in TCM of gastric cancer is relevant to some clinical factors and varies in progress.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631802.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


63. Fahy BN, D'Angelica M, DeMatteo RP, Blumgart LH, Weiser MR, Ostrovnaya I, Gonen M, Jarnagin WR: Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention. Ann Surg Oncol; 2009 Feb;16(2):361-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention.
  • More effective chemotherapeutic agents have broadened the role of hepatic resection in the management of patients with synchronous hepatic metastases from colon cancer.
  • This study examines the management patterns and the role of hepatobiliary surgical evaluation in patients with synchronous stage IV colon cancer.
  • Patients with synchronous hepatic metastases from colon cancer evaluated and treated from 1/99 to 11/04 were analyzed retrospectively.
  • Variables associated with improved DSS included: carcinoembryonic antigen level < or =200 ng/ml, node-negative primary tumor, < or =4 liver metastases, unilobar metastases, largest metastasis < or =5 cm, and hepatic resection.
  • [MeSH-major] Colonic Neoplasms / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoembryonic Antigen / analysis. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050976.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


64. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A: Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol; 2008 Jul;9(7):621-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiofrequency ablation is an accepted treatment for non-surgical patients with liver cancer.
  • Diagnoses included non-small-cell lung cancer (NSCLC) in 33 patients, metastasis from colorectal carcinoma in 53 patients, and metastasis from other primary malignancies in 20 patients.
  • Primary endpoints were technical success (defined as correct placement of the ablation device into all tumour targets with completion of the planned ablation protocol), safety (including identification of treatment-related complications and changes in pulmonary function), and confirmed complete response of tumours (according to modified Response Evaluation Criteria in Solid Tumors).
  • Secondary endpoints were overall survival, cancer-specific survival, and quality of life.
  • Cancer-specific survival was 92% (78-98%) at 1 year and 73% (54-86%) at 2 years in patients with NSCLC, 91% (78-96%) at 1 year and 68% (54-80%) at 2 years in patients with colorectal metastases, and 93% (67-99%) at 1 year and 67% (48-84%) at 2 years in patients with other metastases.
  • Patients with stage I NSCLC (n=13) had a 2-year overall survival of 75% (45-92%) and a 2-year cancer-specific survival of 92% (66-99%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome


65. Sun HW, Chen LH, Wei CJ, Zheng XK, Li QS, Guan J: [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jun;29(6):1133-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
  • OBJECTIVE: To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE).
  • METHODS: From January 2001 to December 2004, 84 patients with unresectable massive PLC (tumor size> or =10 cm) received 3-DCRT combined with TACE, including 49 cases in UICC/AJCC T(3) stage and 35 cases in T(4) stages.
  • Child-Pugh grade A of liver cirrhosis was present in 64 cases and grade B in 20 cases.
  • T stage, GTV, PVTT and fraction size had no significant impact on the overall survival.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Hepatocellular / therapy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Mitomycin / administration & dosage. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726341.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / hydroxycamptothecinum; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


66. Rubie C, Kollmar O, Frick VO, Wagner M, Brittner B, Gräber S, Schilling MK: Differential CXC receptor expression in colorectal carcinomas. Scand J Immunol; 2008 Dec;68(6):635-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we aimed to assess the expression profile of chemokine receptors CXCR1-4 in inflammatory and malignant colorectal diseases and corresponding hepatic metastases of synchronous and metachronous origin to elucidate their role in colorectal cancer (CRC) progression and metastasis.
  • Chemokine receptor expression was assessed by quantitative real-time PCR, immunohistochemistry (IHC) and Western blot analysis in resection specimens from patients with ulcerative colitis (UC, n = 25), colorectal adenomas (CRA, n = 8), different stages of CRC (n = 48) as well as colorectal liver metastases (CRLM) along with their corresponding primary colorectal tumours (n = 16).
  • On the other hand, CXCR3 showed no significant upregulation in either tumour stage, but significant overexpression in CRLM.
  • In conclusion, our findings show a very differential expression pattern of the four receptors in colorectal carcinomas and their corresponding liver metastases with prominent expression profiles that indicate a potential role in the pathogenesis of CRC.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Liver Neoplasms / secondary. Receptors, CXCR / metabolism
  • [MeSH-minor] Adult. Aged. Colitis, Ulcerative / genetics. Colitis, Ulcerative / metabolism. Colitis, Ulcerative / pathology. Female. Gene Expression Profiling. Humans. Male. Microdissection. Middle Aged. Neoplasm Staging. RNA, Neoplasm / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959627.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 0 / Receptors, CXCR
  •  go-up   go-down


67. Theophanous E, Petraki C, Scorilas A, Komborozos V, Veloudis G, Varga JL, Zarandi M, Schally AV, Koutsilieris M: The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. Mol Med; 2009 Jul-Aug;15(7-8):242-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer.
  • Recent evidence demonstrates that splice variants of the GHRH receptor are also expressed in several nonpituitary tissues, both normal and tumoral, as well as in cancer cell lines.
  • The aim of this study was to investigate the expression of the splice variant 1 (SV-1) of GHRH-R in colorectal cancer (CRC).
  • Tumor grade and pathological stage were negatively correlated with expression of SV-1 (P = 0.012 and P = 0.013, respectively).
  • CRCs metastatic to the liver showed a lower expression of SV-1 than did primary tumors, but this difference was not statistically significant.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axin Protein. Cadherins / metabolism. Cohort Studies. Cytoskeletal Proteins / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Protein Isoforms. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Life Sci. 2004 May;61(9):1042-68 [15112052.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1708-13 [14755056.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15160-5 [15469915.001]
  • [Cites] Fertil Steril. 1991 Nov;56(5):888-93 [1936323.001]
  • [Cites] Prostate. 1991;19(4):313-21 [1661415.001]
  • [Cites] Biochem Cell Biol. 1992 May;70(5):273-8 [1323302.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):481-6 [7685989.001]
  • [Cites] J Bone Miner Res. 1994 Nov;9(11):1823-32 [7863832.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3A):1551-7 [9179194.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3098-103 [10077643.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10747-52 [16815967.001]
  • [Cites] Regul Pept. 2006 Sep 11;136(1-3):105-8 [16781787.001]
  • [Cites] J Cell Biochem. 2007 Nov 1;102(4):820-8 [17854061.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):33-43 [18084344.001]
  • [Cites] Regul Pept. 2008 Apr 10;147(1-3):33-6 [18255167.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3645-54 [18483246.001]
  • [Cites] J Surg Res. 2008 Dec;150(2):212-8 [18316097.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6B):3945-60 [19192655.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] Front Neuroendocrinol. 2001 Oct;22(4):248-91 [11587553.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5729-36 [11739429.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Jun;10(6):1099-115 [11772238.001]
  • [Cites] Peptides. 2002 Jun;23(6):1127-33 [12126741.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11866-71 [12186980.001]
  • [Cites] Eur J Endocrinol. 2002 Sep;147(3):381-6 [12213676.001]
  • [Cites] Receptors Channels. 2002;8(3-4):155-62 [12529933.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):44-55 [12568443.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Jun;12(6):933-41 [12783598.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Aug;12(8):1385-94 [12882623.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9512-7 [12867592.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15836-41 [14660794.001]
  • [Cites] Eur J Endocrinol. 2004 Sep;151(3):391-6 [15362970.001]
  • (PMID = 19593408.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AXIN2 protein, human; 0 / Axin Protein; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Protein Isoforms; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / somatotropin releasing hormone receptor
  • [Other-IDs] NLM/ PMC2707517
  •  go-up   go-down


68. Stapley S, Peters TJ, Sharp D, Hamilton W: The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records. Br J Cancer; 2006 Nov 20;95(10):1321-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records.
  • The association between the staging of colorectal cancer and mortality is well known.
  • We performed a cohort study of 349 patients with primary colorectal cancer in whom all their prediagnostic symptoms and investigation results were known.
  • Survival data for 3-8 years after diagnosis were taken from the cancer registry.
  • Rectal bleeding as an initial symptom was associated with less advanced staging (odds ratio from one Duke's stage to the next 0.50, 95% confidence interval 0.31, 0.79; P=0.003) and with reduced mortality (Cox's proportional hazard ratio (HR) 0.56 (0.41, 0.79); P=0.001.
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Constipation / etiology. Diarrhea / etiology. Female. Gastrointestinal Hemorrhage / etiology. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Occult Blood. Predictive Value of Tests. Weight Loss

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1991 Feb;61(2):137-40 [2001199.001]
  • [Cites] Eur J Surg Oncol. 1989 Oct;15(5):441-5 [2551743.001]
  • [Cites] Eur J Surg Oncol. 1999 Apr;25(2):173-8 [10218461.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):3039-45 [10520866.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):169-71 [15720357.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):399-405 [16106247.001]
  • [Cites] Fam Pract. 2006 Feb;23(1):15-9 [16286462.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):423-9 [16684087.001]
  • [Cites] Colorectal Dis. 2006 Jul;8(6):518-21 [16784474.001]
  • [Cites] BMJ. 2006 Jul 8;333(7558):69-70 [16790459.001]
  • [Cites] Colorectal Dis. 2006 Oct;8(8):688-95 [16970580.001]
  • [Cites] BMJ. 2001 Jun 30;322(7302):1555-6 [11431280.001]
  • [Cites] Dig Liver Dis. 2000 May;32(4):312-7 [11515629.001]
  • [Cites] Postgrad Med J. 2002 Sep;78(923):533-7 [12357013.001]
  • [Cites] Ann R Coll Surg Engl. 2002 Nov;84(6):381-5 [12484575.001]
  • [Cites] Scand J Gastroenterol. 2004 Mar;39(3):252-8 [15074395.001]
  • [Cites] World J Surg. 2004 Jul;28(7):716-20 [15383871.001]
  • [Cites] Eur J Surg Oncol. 1986 Jun;12(2):127-30 [3709816.001]
  • [Cites] Eur J Cancer. 1997 Aug;33(9):1461-7 [9337690.001]
  • (PMID = 17060933.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360591
  •  go-up   go-down


69. Iizuka M, Sengoku N, Nakakuma T, Yoshimura N, Hayashi K, Enomoto T, Kuranami M, Watanabe M: [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2228-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
  • We here describe a case of advanced breast cancer (Stage IV) in which an oral S-1+TAM therapy following a primary systemic chemo-radiotherapy has been effective in maintaining the patient's QOL.
  • Subsequently, radiographic imaging tests revealed that the tumor had metastasized to the liver and lungs, as well as the skull.
  • Accordingly, a primary systemic chemotherapy (4 series of AC/T) was started and followed by local radiation therapy (60 Gys) immediately after completing the chemotherapy.
  • The metastasizing lesions in the liver, lungs, and skull had markedly reduced in the size and number, and the skin ulceration had healed up by these treatments.
  • She has been quite well without any adverse effects by S-1 and TAM, and the primary as well as metastasizing lesions remain stable with normalized tumor marker levels (NC) for nearly 3 years.
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Drug Combinations. Female. Humans. Mitoxantrone / therapeutic use. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed. Topotecan / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106579.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 04079A1RDZ / Cytarabine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; AC protocol; TAM protocol
  •  go-up   go-down


70. Jim MA, Perdue DG, Richardson LC, Espey DK, Redd JT, Martin HJ, Kwong SL, Kelly JJ, Henderson JA, Ahmed F: Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004. Cancer; 2008 Sep 1;113(5 Suppl):1244-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004.
  • BACKGROUND: American Indians and Alaska Natives (AI/AN) experience higher morbidity and mortality from primary liver cancer than other United States (US) populations, but racial misclassification in medical records results in underestimates of disease burden.
  • METHODS: To reduce misclassification, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results data were linked with Indian Health Service (IHS) enrollment records to compare primary liver cancer incidence and stage at diagnosis between AI/AN and non-Hispanic whites (NHW) living within the regionalized IHS Contract Health Service Delivery Area counties.
  • Liver cancer incidence rates among AI/AN males and females were higher than those among NHW males and females for all regions except for the East.
  • CONCLUSIONS: Reducing racial misclassification revealed higher disparities in primary liver cancer incidence between NHW and AI/AN populations than previously reported.
  • Further description of the reasons for regional differences in this disparity is needed, as are programs to reduce risk factors and to diagnose primary liver cancer at earlier, more treatable stages.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Native American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720380.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089139; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


71. Hwang JP, Hassan MM: Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer; 2009;9:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation.
  • Anderson Cancer Center.
  • Male gender, high alpha-fetoprotein levels, and stage IV disease were associated with shorter survival Overall median survival was 9.2 months (95% CI 6.5-11.9), and the survival of HCV and HBV patients was not statistically different.
  • Timely hepatitis screening and interventions by primary care physicians may be the most logical solution to reduce the burden of hepatitis-associated HCC among Asian Americans.
  • [MeSH-major] Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / mortality. Hepatitis / complications. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Asian Americans. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors. Survival. alpha-Fetoproteins / metabolism


72. Zhang L, Ren ZG, Gan YH, Wang YH, Zhang BH, Chen Y, Xie XY, Ge NL, Ye SL: [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):630-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC).
  • METHODS: During the period from December 2005 to March 2009, 50 patients with unresectable primary HCC of Child-Pugh status A were treated with sorafenib (400 mg, Bid).
  • The common adverse events were dermal reaction (68.0%, 34/50), diarrhea (52.0%, 26/50), hypertension (4.0%, 2/50), hair loss (14.0%, 7/50), myelosuppression (16.0%, 8/50), and liver dysfunction (20.0%, 10/50).
  • CONCLUSION: Soafenib is effective for unresectable primary HCC with tolerable toxicity.
  • Tumor stage is a predominant prognostic factor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Chemoembolization, Therapeutic / methods. Diarrhea / chemically induced. Disease Progression. Follow-Up Studies. Humans. Hypertension / chemically induced. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Skin Diseases / chemically induced. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122420.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


73. Agrawal S, McCarron EC, Gibbs JF, Nava HR, Wilding GE, Rajput A: Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol; 2007 Aug;14(8):2263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management and outcome in primary adenocarcinoma of the small bowel.
  • BACKGROUND: Primary adenocarcinoma of the small bowel is a rare malignancy and is associated with poor survival outcome.
  • METHODS: Between 1971 and 2005, 64 patients with primary adenocarcinoma of the small bowel were treated at our institution.
  • The most common sites of recurrence following a curative resection were the liver and lung.
  • On multivariate analysis, absence of distant metastatic disease (5-year survival 30.4%), curative resection (5-year survival 44.8%) and pathological T stage 1-3 (5-year survival 39.2%) were identified as independent predictors of survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Rate. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549572.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG: Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol; 2005 Jul;174(1):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience.
  • PURPOSE: Primary neuroendocrine tumors of the bladder are rare and they include small and large cell variants.
  • MATERIALS AND METHODS: From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer at our institution, of whom 25 (1.2%) had neuroendocrine tumors of the bladder, including small cell carcinoma in 20 and large cell carcinoma in 5.
  • A total of 19 patients (76%) had lymph node involvement, of whom 2 had small liver metastases found intraoperatively, while only 4 (16%) had organ confined tumors and 2 (8%) had extravesical, node negative disease.
  • CONCLUSIONS: Neuroendocrine tumors of the bladder usually present with advanced pathological stage and portend a poor prognosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947585.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C: Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer; 2010 Sep 07;103(6):837-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks.
  • The primary aim of the study was progression-free survival (PFS).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Neovascularization, Pathologic / drug therapy. Oligopeptides / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2000 Nov;18(11):1185-90 [11062439.001]
  • [Cites] Clin Cancer Res. 2010 Feb 15;16(4):1315-23 [20145168.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):475-82 [12189241.001]
  • [Cites] FASEB J. 2004 Mar;18(3):554-6 [14734634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 [1103152.001]
  • [Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:104-12 [15650236.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6657-63 [16170173.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):175-82 [16397040.001]
  • [Cites] Cancer Immun. 2006;6:6 [16551058.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4588-93 [17360568.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):581-9 [17583545.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):845-53 [17599769.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1059-67 [17623837.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2992-8 [18565886.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):19-23 [19018262.001]
  • [Cites] Br J Cancer. 2009 Jul 21;101(2):219-24 [19568235.001]
  • [Cites] Eur J Cancer. 2010 Jan;46(1):198-206 [19900802.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):867-74 [11830545.001]
  • (PMID = 20717115.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / NGR peptide; 0 / Oligopeptides; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2966632
  •  go-up   go-down


76. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS: Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res; 2009;28:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is the most common tumor in the adult liver, with high relapse and mortality rates despite diverse treatment modalities.
  • METHODS: Frozen tumors and non-cancerous surrounding tissues from 120 patients with primary HCC were studied.
  • RESULTS: NNMT mRNA level is markedly reduced in HCCs compared to non-cancerous surrounding tissues (P < 0.0001), and NNMT expression in tumors was significantly correlated with tumor stage (P = 0.010).
  • Both NNMT expression (P = 0.0096) and tumor stage (P = 0.0017) were found to be significant prognostic factors for DFS in a multivariate analysis.
  • CONCLUSION: The results of this study indicated that NNMT gene expression is associated with tumor stage and DFS time in HCC cases.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. Nicotinamide N-Methyltransferase / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cohort Studies. Disease-Free Survival. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1991 Nov;82(11):1277-83 [1836457.001]
  • [Cites] Clin Chim Acta. 1990 Jan 31;186(3):359-74 [2311261.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14835-40 [8182091.001]
  • [Cites] J Hepatol. 1994 Jan;20(1):138-42 [8201215.001]
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Oncol Res. 2004;14(10):491-9 [15559763.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):527-39 [15486044.001]
  • [Cites] J Pathol. 2005 Feb;205(3):377-87 [15682440.001]
  • [Cites] Toxicol Pathol. 2005;33(1):175-80 [15805069.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] J Urol. 2006 Nov;176(5):2248-54 [17070307.001]
  • [Cites] Exp Mol Med. 2006 Oct 31;38(5):455-65 [17079861.001]
  • [Cites] BMC Bioinformatics. 2007;8:66 [17326819.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 May;134(5):551-9 [17922140.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4814-20 [18676753.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6679-89 [18724390.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9167-75 [19010888.001]
  • [Cites] Physiol Genomics. 2001 Feb 7;5(1):21-33 [11161003.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4568-75 [11494152.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Feb;61(2):111-24 [11853016.001]
  • [Cites] Hepatology. 2002 May;35(5):1237-46 [11981774.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3939-44 [12124323.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S136-49 [12591191.001]
  • [Cites] Neurosci Lett. 2003 May 15;342(1-2):13-6 [12727306.001]
  • [Cites] Curr Mol Med. 2003 Sep;3(6):573-88 [14527088.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4990-6 [14557485.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):129-37 [15324696.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S51-5 [15508103.001]
  • [Cites] Gastroenterology. 1981 Oct;81(4):668-75 [7262512.001]
  • [Cites] Hepatology. 1988 Jan-Feb;8(1):65-8 [3338721.001]
  • [Cites] Arch Biochem Biophys. 1988 Feb 1;260(2):601-8 [2963591.001]
  • [Cites] Tumour Biol. 1994;15(1):7-16 [8146531.001]
  • (PMID = 19216803.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.1.1.1 / NNMT protein, human; EC 2.1.1.1 / Nicotinamide N-Methyltransferase
  • [Other-IDs] NLM/ PMC2657806
  •  go-up   go-down


77. Alazmi W, Bustamante M, O'Loughlin C, Gonzalez J, Raskin JB: The association of Streptococcus bovis bacteremia and gastrointestinal diseases: a retrospective analysis. Dig Dis Sci; 2006 Apr;51(4):732-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is a well-established association between Streptococcus bovis bacteremia (SBB) and colorectal cancer.
  • However, SBB is also frequently associated with chronic liver disease and has been described with other gastrointestinal disorders.
  • Nine adult patients (19%) had end-stage liver disease (five female).
  • Six patients had alcohol-induced liver disease (one with concomitant chronic hepatitis C), with the remaining three cases related to autoimmune hepatitis, primary biliary cirrhosis, and nonalcoholic steatohepatitis.
  • Colonic neoplasms (adenocarcinoma in 3 and adenomatous polyps in 3) were found in 6 of 10 adult patients in whom colonoscopic evaluation was performed.
  • Seven adult patients had acquired immunodeficiency syndrome (AIDS) (18%).
  • This association was valid for our adult population only.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Comorbidity. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Registries. Retrospective Studies. Severity of Illness Index. Sex Distribution. Survival Analysis

  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1977 Dec 15;297(24):1354-5 [917098.001]
  • [Cites] JAMA. 1981 Jan 23-30;245(4):360-3 [7452862.001]
  • [Cites] Conn Med. 1981 Mar;45(3):139-40 [7238020.001]
  • [Cites] Ann Intern Med. 1979 Oct;91(4):560-2 [484953.001]
  • [Cites] J Clin Pathol. 1978 Dec;31(12):1182-6 [107199.001]
  • [Cites] J Bacteriol. 1945 Jun;49(6):603-10 [16560959.001]
  • [Cites] Gastrointest Endosc. 2000 Dec;52(6):796-8 [11115925.001]
  • [Cites] Ann Intern Med. 1980 Mar;92(3):441 [7356254.001]
  • [Cites] Arch Intern Med. 1978 Jul;138(7):1097-9 [666468.001]
  • [Cites] Scand J Infect Dis. 1988;20(4):459-60 [3194717.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):760-5 [15249410.001]
  • [Cites] N Engl J Med. 1970 Jan 15;282(3):123-8 [4982606.001]
  • [Cites] Br Med J. 1976 Jun 26;1(6025):1568-9 [1276771.001]
  • [Cites] J Bacteriol. 1946 Jun;51(6):790 [16561135.001]
  • [Cites] Scand J Gastroenterol. 1986 Mar;21(2):151-7 [3715384.001]
  • [Cites] N Engl J Med. 1978 Mar 9;298(10):572-3 [625315.001]
  • [Cites] Am J Surg. 1988 Feb;155(2):343-7 [3341559.001]
  • [Cites] Am J Clin Nutr. 1974 Dec;27(12 ):1481-5 [4611196.001]
  • [Cites] Ann Intern Med. 1978 Dec;89(6):1009-10 [717979.001]
  • [Cites] N Engl J Med. 1977 Oct 13;297(15):800-2 [408687.001]
  • [Cites] J Clin Microbiol. 1983 Apr;17(4):696-7 [6853693.001]
  • [Cites] Postgrad Med J. 1992 Nov;68(805):930-1 [1494518.001]
  • [Cites] Ann Surg. 1990 Jun;211(6):786-91; discussion 791-2 [2357141.001]
  • [Cites] Lancet. 1987 Mar 28;1(8535):748 [2882164.001]
  • (PMID = 16614996.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H: Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol; 2006 Aug;169(2):471-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.
  • Whereas no correlation was found between the JAK2 status and MMP gene products, there was an evident association with the stage of disease.
  • We conclude that the expression of matrix-modeling genes in cIMF is not influenced by the JAK2 mutation status but is predominantly related to the stage of disease.
  • [MeSH-major] Collagenases / genetics. Mutation / genetics. Primary Myelofibrosis / enzymology. Primary Myelofibrosis / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / enzymology. Disease Progression. Endothelial Cells / enzymology. Endothelial Cells / pathology. Female. Fibrosis / pathology. Hematopoiesis / genetics. Humans. Janus Kinase 2. Male. Matrix Metalloproteinases / genetics. Megakaryocytes / enzymology. Megakaryocytes / pathology. Middle Aged. Protein Transport. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tissue Inhibitor of Metalloproteinases / genetics. Up-Regulation / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2006 May;8(2):170-7 [16645202.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):248-58 [16397238.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3374-80 [11071630.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3491-8 [11207308.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):116-7 [11476553.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):195-204 [11722433.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Methods. 2001 Dec;25(4):409-18 [11846610.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):709-12 [12437648.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):152-8 [12520711.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):276-82 [12950237.001]
  • [Cites] Acta Haematol. 2004;111(3):155-9 [15034237.001]
  • [Cites] Cell Adhes Commun. 1993 Sep;1(2):93-9 [8081879.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4641-51 [9845530.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2627-36 [10194442.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1227-37 [15284024.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Pathol. 2005 Apr;205(5):548-57 [15726648.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4508-15 [15705794.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4187-90 [15817681.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):76-82 [15982347.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1128-32 [16079113.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1261-8 [16109602.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4):248-58 [16210038.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5487-93 [16213498.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8520-30 [16293880.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • (PMID = 16877349.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC1780160
  •  go-up   go-down


79. de Ferro SM, Suspiro A, Fidalgo P, Lage P, Rodrigues P, Fragoso S, Vitoriano I, Baltazar C, Albuquerque C, Bettencourt A, Leitão CN: Aggressive phenotype of MYH-associated polyposis with jejunal cancer and intra-abdominal desmoid tumor: report of a case. Dis Colon Rectum; 2009 Apr;52(4):742-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive phenotype of MYH-associated polyposis with jejunal cancer and intra-abdominal desmoid tumor: report of a case.
  • MYH-associated polyposis is an inherited autosomal recessive disease, linked to biallelic germline MYH mutations, which predisposes to the development of multiple colorectal adenomas and cancer.
  • At aged 35 years, Spigelman Stage IV duodenal adenomatosis was detected.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Colorectal Neoplasms / genetics. Fibromatosis, Aggressive / genetics. Jejunal Neoplasms / genetics. Neoplasms, Multiple Primary / genetics. Peritoneal Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenoma / genetics. Adult. DNA Glycosylases / genetics. Duodenal Neoplasms / genetics. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Intestinal Neoplasms / genetics. Intestinal Obstruction / etiology. Liver Neoplasms / secondary. Male. Mesentery. Mutation. Phenotype. Syndrome


80. Biswas G, Khadwal A, Kulkarni P, Bakshi A, Nair C, Kurkure P, Muckaden M, Parikh P: Ewing's sarcoma with cutaneous metastasis--a rare entity: report of three cases. Indian J Dermatol Venereol Leprol; 2005 Nov-Dec;71(6):423-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is curable when diagnosed in the localized stage and requires multimodality treatment.
  • Less common sites of metastasis are lymph nodes, CNS and liver.
  • It occurs in up to 9% of all patients with cancer.
  • Growth pattern of cutaneous metastasis is unpredictable and may not reflect that of primary tumor.
  • [MeSH-minor] Adolescent. Adult. Child. Fatal Outcome. Female. Humans. Male

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16394487.001).
  • [ISSN] 0378-6323
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


81. Hu JL, Huang JJ, Fu XH: [Survival status and prognostic factors of liver metastases from colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):286-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival status and prognostic factors of liver metastases from colorectal cancer].
  • OBJECTIVE: To analyze the survival status and prognostic factors of patients with liver metastases from colorectal cancer.
  • METHODS: The survival rate and prognostic factors of 112 patients with liver metastases from colorectal cancer, who had complete follow-up data, were retrospectively assessed by Kaplan-Meier analysis and multivariate regression analysis.
  • Univariate analysis demonstrated that gender, age, primary tumor site, chemotherapy and pathological types had no significant correlation with the overall survival.
  • But the treatment of primary tumor, time of liver metastasis, gross type of tumor, resection of liver metastases and clinical stage status were all independently related with the prognosis of patients.
  • Multivariate regression analysis showed that resection of liver metastases, gross type of tumor and clinical stage were key factors affecting the prognosis of patients with liver metastases from colorectal cancer.
  • CONCLUSION: Patients with advanced stage, infiltrative gross type of colorectal cancer should be followed-up closely so that liver metastases from the cancer can be diagnosed and treated early.
  • Resection of both the primary tumor and liver metastasis may improve survival of the patients.
  • [MeSH-major] Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510081.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


82. Idasiak A, Masłyk B, Blamek S, Suwiński R: [Risk of distant metastases after postoperative radiation therapy for locally advanced laryngeal cancer]. Otolaryngol Pol; 2008;62(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk of distant metastases after postoperative radiation therapy for locally advanced laryngeal cancer].
  • PURPOSE: To evaluate the prognostic factors for the risk of distant metastases after postoperative radiotherapy for laryngeal cancer.
  • MATERIAL AND METHODS: Medical records of 267 patients cancer treated between 1997 and 2003 were analyzed.
  • All pts had locally advanced squamous cell laryngeal cancer treated with surgery and postoperative radiotherapy.
  • A multivariate Cox proportional hazard model and logistic regression model was used to evaluated influence of the following variables on MFS and the ultimate risk of metastases: age, sex, localization, TN stage, HGB before and at the end radiotherapy, total radiation dose, dose per fraction, overall treatment time, interval surgery-radiation time, pathological margins and positive nodes in surgical specimen.
  • The lungs and bones were the most common sites of metastases (58% and 33% respectively), whereas metastases to liver (6%) and brain (3%) were rare.
  • Localization of cancer (glottic vs. supraglottic) and number of positive lymph nodes at pathological staging significantly and independently affected MFS.
  • CONCLUSIONS: Number of positive lymph nodes in pathological specimen and site of primary cancer (glottic vs. supraglottic) significantly and independently predict a risk of distant metastases in combined modality treatment for laryngeal cancer.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Incidence. Laryngectomy / statistics & numerical data. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Poland / epidemiology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637438.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


83. Obed A, Tsui TY, Schnitzbauer AA, Obed M, Schlitt HJ, Becker H, Lorf T: Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg; 2008 Mar;393(2):141-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified?
  • BACKGROUND: Liver transplantation is considered as one of therapeutic approaches to hepatocellular carcinoma (HCC).
  • Patients were treated either with primary tumour resection, transarterial chemoembolisation (TACE) or liver transplantation (LTx) by an interdisciplinary team.
  • RESULTS: The overall 1-year and 5-year survivals of patients in LTx group were 95 and 57%, respectively, which were significantly higher than those in primary tumour resection group (65 and 33%, P < 0.01) and those in TACE group (44 and 4%, P < 0.01).
  • In parallel, 1-year and 5-year tumour-free survivals of patients in LTx group (75 and 62%) were significantly higher than those in primary tumour resection group (50 and 11%, P < 0.01).
  • There were no significant differences in 1- and 5-year survivals of patients with early tumour stage received LTx or primary tumour resection, whereas patients in advanced tumour stage based on pathological findings of explanted liver significantly benefited from LTx as compared to primary resection.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Liver Transpl. 2006 Aug;12(8):1260-7 [16826556.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):877-83 [11679986.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):474-86 [11685740.001]
  • [Cites] Ann Surg. 2002 May;235(5):722-30; discussion 730-1 [11981219.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9 [14530722.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):145-51 [8393649.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:9-16 [9210883.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1572-7 [9620329.001]
  • [Cites] Transpl Int. 1998;11 Suppl 1:S189-92 [9664976.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] J Hepatol. 1998 Dec;29(6):953-9 [9875642.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):324-31 [10458250.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S113-9 [16286887.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):212-7 [16613896.001]
  • [Cites] Transplant Proc. 2006 May;38(4):1111-3 [16757280.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1224-9 [11093728.001]
  • (PMID = 18043937.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3085731
  •  go-up   go-down


84. Ramírez Plaza CP, Santoyo Santoyo J, Domínguez López ME, Eloy-García Carrasco C, Cobo Dols M, Suárez Muñoz MA, Fernández Aguilar JL, de la Fuente Perucho A: [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy]. Arch Esp Urol; 2005 Mar;58(2):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy].
  • METHODS/RESULTS: We report the case of a 29-year-old female patient who consulted for left flank pain, being diagnosed of an adrenal tumor by radiological tests; she underwent surgical excision of a left adrenal carcinoma (stage II).
  • Later on she presented with local-regional recurrences (2 times) and distant metastases (liver) undergoing excision in three procedures.
  • CONCLUSIONS: Adrenal cancer recurrences have been considered lethal in the short-term.
  • Nevertheless, an aggressive surgical approach of local recurrences and metastasic disease may significantly prolong patient's survival and, sometimes, leave the patient disease free several years after the diagnosis of the primary tumor.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Reoperation. Time Factors

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847268.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


85. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, Hiramatsu A, Kodama H, Takahashi S, Chayama K: Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol; 2007 Jan 21;13(3):414-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To assess the clinical features and prognosis of 151 patients with extrahepatic metastases from primary hepatocellular carcinoma (HCC), and describe the treatment strategy for such patients.
  • METHODS: After the diagnosis of HCC, all 995 consecutive HCC patients were followed up at regular intervals and 151 (15.2%) patients were found to have extrahepatic metastases at the initial diagnosis of primary HCC or developed such tumors during the follow-up period.
  • Fourteen patients (11%) died of extrahepatic HCC, others died of primary HCC or liver failure.
  • Although most of HCC patients with extrahepatic metastases should undergo treatment for the primary HCC mainly, treatment of extrahepatic metastases in selected HCC patients who have good hepatic reserve, intrahepatic tumor stage (T0-T2), and are free of portal venous invasion may improve survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cause of Death. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / mortality. Liver Neoplasms / therapy. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / therapy. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1049-52 [10370665.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1198-200 [9752858.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):61-7 [15709088.001]
  • [Cites] Cardiovasc Intervent Radiol. 2005 Sep-Oct;28(5):578-83 [16059766.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1067-76 [15913915.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):63-70 [11420484.001]
  • [Cites] Dig Surg. 2001;18(4):294-7 [11528139.001]
  • [Cites] J Gastroenterol. 2002;37(7):571-4 [12162418.001]
  • [Cites] Surg Today. 2002;32(12):1035-41 [12541019.001]
  • [Cites] Am Surg. 2003 Oct;69(10):879-85 [14570367.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Cancer. 1985 May 1;55(9):1991-4 [2983871.001]
  • [Cites] Clin Nucl Med. 1992 Feb;17(2):99-100 [1314154.001]
  • [Cites] Int J Dermatol. 1992 Apr;31(4):273-6 [1321795.001]
  • [Cites] Gastroenterol Jpn. 1993 Apr;28(2):312-6 [8387439.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):316-9 [7691699.001]
  • [Cites] Clin Orthop Relat Res. 1994 Jun;(303):237-41 [8194240.001]
  • [Cites] Abdom Imaging. 1994 Jul-Aug;19(4):309-12 [8075551.001]
  • [Cites] Br J Surg. 1994 Jul;81(7):1019-21 [7922051.001]
  • [Cites] J Am Soc Echocardiogr. 1994 Sep-Oct;7(5):547-9 [7986554.001]
  • [Cites] Chin Med J (Engl). 1995 Aug;108(8):568-70 [7587484.001]
  • [Cites] World J Gastroenterol. 2006 Mar 28;12(12):1969-71 [16610010.001]
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):251-7 [9058154.001]
  • [Cites] Jpn J Clin Oncol. 2004 Dec;34(12):733-9 [15640504.001]
  • (PMID = 17230611.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4065897
  •  go-up   go-down


86. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol; 2009 Mar;16(3):623-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma is a very rare form of primary liver cancer containing components of both tumor types.
  • PATIENTS AND METHODS: Of the 2427 patients who underwent hepatectomy or liver transplantation because of a primary hepatic malignancy from January 1989 to July 2006 at the Asan Medical Center, Seoul, Korea, 29 had hepatocellular carcinoma and cholangiocarcinoma as a single mixed or transitional tumor.
  • Univariate analysis showed that CA 19-9 above 37 U/ml was predictive of low overall survival (P= .03) and that TNM stage was significantly associated with disease-free survival (P= .04).
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Liver Transplantation. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130133.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Beham A, Rentsch M, Püllmann K, Mantouvalou L, Spatz H, Schlitt HJ, Obed A: Survival benefit in patients after palliative resection vs non-resection colon cancer surgery. World J Gastroenterol; 2006 Nov 7;12(41):6634-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefit in patients after palliative resection vs non-resection colon cancer surgery.
  • AIM: To evaluate survival in patients undergoing palliative resection versus non-resection surgery for primary colorectal cancer in a retrospective analysis.
  • METHODS: Demographics, TNM status, operating details and survival were reviewed for 67 patients undergoing surgery for incurable colorectal cancer.
  • Palliative resection of the primary tumor was performed in 46 cases in contrast to 21 patients with non-resection of the primary tumor and bypass surgery.
  • RESULTS: The two groups were comparable in terms of age, gender, preoperative presence of ileus and tumor stage.
  • CONCLUSION: Palliative resection surgery for primary colorectal cancer is associated with a higher median survival rate.
  • Also, the presence of liver metastasis and tumor size are associated with poor survival.
  • Therefore, resection of the primary tumor should be considered in patients with non-curable colon cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] Radiology. 1999 Jan;210(1):65-9 [9885588.001]
  • [Cites] Eur Radiol. 2002 Sep;12(9):2250-2 [12195477.001]
  • [Cites] Bioessays. 2003 Jan;25(1):79-86 [12508286.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):27-34 [12667306.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):39-43 [14719149.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] Arch Surg. 1987 Jun;122(6):640-3 [2437881.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1559-65 [2443619.001]
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):636-52 [3042304.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):491-501 [2407810.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):846-50 [1698594.001]
  • [Cites] BMJ. 1993 Mar 20;306(6880):752-5 [7683942.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):34-5 [7881950.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):11-4 [9102251.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):432-6 [9106691.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] Br J Cancer. 2000 Nov;83(9):1216-22 [11027436.001]
  • (PMID = 17075976.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4125668
  •  go-up   go-down


88. Pourhoseingholi MA, Moghimi-Dehkordi B, Safaee A, Hajizadeh E, Solhpour A, Zali MR: Prognostic factors in gastric cancer using log-normal censored regression model. Indian J Med Res; 2009 Mar;129(3):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in gastric cancer using log-normal censored regression model.
  • BACKGROUND & OBJECTIVE: Gastric cancer is one of the most common cancers in the world.
  • We used log normal regression model in this study to evaluate prognostic factors in gastric cancer and compared with Cox model.
  • METHODS: We retrospectively studied the 746 patients diagnosed with gastric cancer admitted in a referral hospital in Tehran, Iran, from February 2003 through January 2007.
  • Age at diagnosis, sex, extent of wall penetration, histology type, tumour grade, tumour size, pathologic stage, lymph node metastasis and presence of metastasis were entered into a log normal model.
  • Patients with greater tumour size were also in higher risk of death followed by those with poorly differentiated and moderately differentiated in tumour grade and advanced pathologic stage.
  • INTERPRETATION & CONCLUSION: Our results suggest that early detection of patients in younger age and in primary stages and grade of tumour could be important to decrease the risk of death in patients with gastric cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Iran / epidemiology. Logistic Models. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491418.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  •  go-up   go-down


89. Lou HZ, Pan HM, Jin W: [Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 May;27(5):393-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation].
  • OBJECTIVE: To investigate the therapeutic efficacy and adverse reactions of Aidi Injection (AI) combined with percutaneous cool-tip radiofrequency ablation (CRFA) in treatment of primary liver cancer and to explore its effect on immune function.
  • METHODS: Eighty-nine patients with primary liver cancer at middle-late stage were assigned to the control group with CRFA alone and the treatment group treated with CRFA and intravenous dripping of AI 50 mL once every day for succesive 20 days.
  • CONCLUSION: AI treatment could relieve the impairment of CRFA on hepatic function, improve immune function and reduce relapse rate in patients with primary liver cancer.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650788.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / aidi herbal drug
  •  go-up   go-down


90. Stang A, Keles H, Hentschke S, Seydewitz C, Keuchel M, Pohland C, Dahlke J, Weilert H, Wessling J, Malzfeldt E: Real-time ultrasonography-computed tomography fusion imaging for staging of hepatic metastatic involvement in patients with colorectal cancer: initial results from comparison to US seeing separate CT images and to multidetector-row CT alone. Invest Radiol; 2010 Aug;45(8):491-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time ultrasonography-computed tomography fusion imaging for staging of hepatic metastatic involvement in patients with colorectal cancer: initial results from comparison to US seeing separate CT images and to multidetector-row CT alone.
  • OBJECTIVES: To prospectively evaluate the role of real-time ultrasonography (US)-computed tomography (CT) fusion imaging (US-CT) in comparison with US seeing separate CT images (US + CT) and multidetector-row CT (MDCT) for the correct staging of hepatic metastatic involvement in patients with colorectal cancer.
  • METHODS: Sixty-four patients with newly diagnosed colorectal cancer and who were referred for abdominopelvic staging before primary tumor resection underwent same-day MDCT, US + CT, and US-CT.
  • Investigators recorded the size and location of detected lesions on segmental liver maps, classified them as being benign, malignant, or indeterminate, and finally assessed the M stage of the liver as being M0, M1, or Mx (indeterminate).
  • Regarding the 45 < or = 1 cm liver lesions, rates for detection were significantly higher (P < 0.05) for MDCT (80%, 36/45) and US-CT (77.8%, 35/45) than for US + CT (64.4%, 29/45); the rate for correct classification by US-CT (71.1%, 32/45) was significantly higher than for US + CT (48.9%, 22/45) and MDCT (31.1%, 14/45) (all P < 0.05).
  • In 13 patients (59 lesions) with only benign (stage M0) or coexistent benign and malignant lesions (stage M1), indeterminate lesion ratings and indeterminate liver stagings (Mx) occurred both significantly lower (P < 0.05) with US-CT (3.4%, 2/59; and 0%, 0/13) than with US + CT (11.9%, 7/59; and 23.1%, 3/13) or with MDCT (30.5%, 18/59; and 53.8%, 7/13).
  • CONCLUSIONS: Based on these initial diagnostic experiences, complementary US-CT fusion imaging of small CT-indeterminate liver lesions may have value in staging patients with colorectal cancer, focusing on patients who were likely to harbor only benign or coexisting benign and malignant liver lesions and in whom change of M staging would change the clinical management.
  • [MeSH-major] Colorectal Neoplasms / pathology. Computer Systems. Liver Neoplasms / diagnosis. Tomography, X-Ray Computed / instrumentation. Ultrasonography / instrumentation
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Time Factors. Tomography, Spiral Computed / instrumentation. Tomography, Spiral Computed / methods


91. Liang SX, Jiang GL, Zhu XD, Fu XL, Li FX, Huang QF, Wang AY, Chen L, Lu HJ: [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy]. Zhonghua Zhong Liu Za Zhi; 2005 Oct;27(10):613-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy].
  • OBJECTIVE: To evaluate the toxicity and efficacy of primary liver cancer (PLC) treated by hypofractionated three-dimensional conformal radiotherapy (3DCRT) and investigate the prognostic factors.
  • 108 patients had Child-Pugh Grade A liver cirrhosis and 20 Child-Pugh Grade B liver cirrhosis.
  • T stage (P = 0.001), GTV (P = 0.0001), PVTT (P = 0.0001) and Child-Pugh Grade (P = 0.0001) had significant impact on the overall survival.
  • CONCLUSION: T stage, GTV, PVTT and Child-Pugh Grade have significant impact on the overall survival in primary liver cancer patients treated by three-dimensional conformal radiotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438872.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Tralhão JG, Hoti E, Serôdio M, Laranjeiro P, Paiva A, Abrantes AM, Pais ML, Botelho MF, Castro Sousa F: Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer. Eur J Surg Oncol; 2010 Feb;36(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer.
  • INTRODUCTION: Although there is general correlation between the TNM stage of colorectal cancer (CRC) and its prognosis, there is often significant variability of tumor behaviour and individual patient outcome, which is unaccounted for by pathologic factors alone.
  • Our aim was to estimate perioperative tumor cell dissemination in patients with primary or CRC liver metastases as a possible factor influencing the outcome.
  • Sixteen patients (47%) had CRC liver metastases only.
  • The remaining six patients who underwent colon or liver resection for benign conditions, acted as the control group.
  • [MeSH-major] Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Colectomy / adverse effects. Female. Flow Cytometry. Hepatectomy / adverse effects. Humans. Male. Middle Aged. Prognosis


93. Thomakos N, Rodolakis A, Belitsos P, Zagouri F, Chatzinikolaou I, Dimopoulos AM, Papadimitriou CA, Antsaklis A: Gestational trophoblastic neoplasia with retroperitoneal metastases: a fatal complication. World J Surg Oncol; 2010;8:114
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its course can be complicated by metastases to distant sites such as the lung, brain, liver, kidney and vagina.
  • The prognosis depends on many prognostic factors that determine the stage of the disease.
  • Accordingly she received chemotherapy as primary treatment but unfortunately developed massive bleeding after the first course of chemotherapy, was operated in an attempt to control bleeding but finally succumbed.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Pregnancy

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):552-7 [14675675.001]
  • [Cites] J Reprod Med. 2004 Jun;49(6):411-4 [15283046.001]
  • [Cites] J Reprod Med. 2002 Jun;47(6):465-71 [12092015.001]
  • [Cites] Am J Obstet Gynecol. 2011 Jan;204(1):11-8 [20739008.001]
  • [Cites] Lancet. 2010 Aug 28;376(9742):717-29 [20673583.001]
  • [Cites] J Reprod Med. 2010 Jul-Aug;55(7-8):333-40 [20795348.001]
  • [Cites] J Reprod Med. 2010 Jul-Aug;55(7-8):296-300 [20795341.001]
  • [Cites] Med Oncol. 2009;26(1):96-100 [18506643.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):258-62 [17291263.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):713-5 [15863190.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):618-23 [15863169.001]
  • [Cites] Med Hypotheses. 2005;64(4):689-93 [15694683.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):192-4 [9740689.001]
  • [Cites] J Reprod Med. 1998 Jan;43(1):75-80 [9475153.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2636-43 [9215835.001]
  • [Cites] Br J Obstet Gynaecol. 1995 Sep;102(9):715-9 [7547762.001]
  • [Cites] J Reprod Med. 1994 Mar;39(3):179-84 [7518516.001]
  • [Cites] Obstet Gynecol. 1994 Jan;83(1):113-7 [8272290.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1074-6 [1970378.001]
  • [Cites] Gynecol Oncol. 1989 Jul;34(1):54-6 [2544490.001]
  • [Cites] Br J Obstet Gynaecol. 1988 Jan;95(1):70-4 [2829961.001]
  • [Cites] J Reprod Med. 1987 Sep;32(9):663-8 [2822920.001]
  • [Cites] Am J Obstet Gynecol. 1984 Mar 15;148(6):711-6 [6702938.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):575-85 [15196847.001]
  • [Cites] Obstet Gynecol. 1980 Jan;55(1):89-94 [6243407.001]
  • [Cites] J Reprod Med. 2002 Aug;47(8):689-92 [12216440.001]
  • (PMID = 21192785.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC3023729
  •  go-up   go-down


94. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY: Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med; 2005 Aug 31;37(4):276-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To elucidate the potential etiological role of the RUNX3 gene in the development of hepatocellular carcinoma (HCC), we have analyzed the methylation status of 5' CpG island of the RUNX3 gene in a series of 73 HCC tissues and 11 liver cell lines.
  • Expectedly, promoter methylation of RUNX3 gene was found in 2 (2.7%) of 73 corresponding normal liver, whereas 30 (41.1%) of 73 HCCs and 4 (40%) of 10 liver cancer cell lines showed hypermethylation of the gene, respectively.
  • There was no significant difference between promoter hypermethylaion and clinicopathologic parameters of primary HCC samples, including histologic grade, microvascular invasion, and clinical stage.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Neoplasm / metabolism. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155404.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


95. Desai SP, El-Rayes BF, Ben-Josef E, Greenson JK, Knol JA, Huang EH, Griffith KA, Philip PA, McGinn CJ, Zalupski MM: A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. Am J Clin Oncol; 2007 Aug;30(4):340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
  • OBJECTIVES: The purpose of this study was to evaluate the safety and efficacy of preoperative capecitabine and radiation therapy (RT) in patients with locally advanced rectal cancer (LARC).
  • METHODS: Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50.4 Gy of RT in 28 1.8-Gy fractions.
  • Patients with metastatic disease were eligible provided that operative intervention on primary site was anticipated.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Capecitabine. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Preoperative Care. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762432.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA091975
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Chen MS, Zhang YJ, Li JQ, Liang HH, Zhang YQ, Lin XJ, Zheng Y, Xu L, Wan YL: [Experience of radiofrequency ablation on liver malignancies: a report of 803 cases]. Zhonghua Wai Ke Za Zhi; 2007 Nov 1;45(21):1469-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of radiofrequency ablation on liver malignancies: a report of 803 cases].
  • OBJECTIVE: To summarize the 8-year experience of radiofrequency ablation (RFA) on liver malignancies and explore the effect and prognostic factors.
  • METHODS: From August 1999 to February 2007, 803 patients with liver malignancies, among which there were 672 with primary liver cancer (PLC) and 131 with liver metastasis, were treated with RFA.
  • RESULTS: In the treatment of all the 803 patients with liver malignancies, the mortality was 0.25%, the rate of severe complications was 0.37%.
  • For the 672 patients with PLCs, the 1, 2, 3, 4, 5-year survivals with stage Ia (Chinese staging system) were 97.8%, 91.5%, 84.6%, 77.1% and 61.9%, respectively, with stage Ib were 93.9%, 83.7%, 69.8%, 45.1% and 42.2%, respectively, with stage II were 86.2%, 67.3%, 47.3%, 17.2% and 0, respectively, and the 1, 2-year survivals with stage III were 67.8% and 0, respectively (P < 0.01).
  • CONCLUSIONS: RFA is a safe and effective method for liver malignancy, and the tumor size and stage are important prognostic factors.
  • [MeSH-major] Catheter Ablation. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275711.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


97. Clements D, Dhruva Rao P, Ramanathan D, Adams R, Maughan TS, Davies MM: Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Dis; 2009 Oct;11(8):845-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.
  • OBJECTIVE: The management of the asymptomatic primary in stage IV colorectal cancer presents a dilemma.
  • Nonresectional management of the primary is associated with the risks of obstruction, perforation or haemorrhage.
  • Our practice in patients with stage IV disease is palliative chemotherapy and symptom control.
  • We reviewed our nonoperatively managed patients with colorectal liver metastases in order to identify the percentage of patients requiring urgent operative interventions for symptoms related to the primary.
  • SUBJECTS/PATIENTS AND METHOD: A retrospective review of all patients treated for stage IV disease at our institution from 2003-2006 was undertaken.
  • There were no similarities between these three patients in terms of age, sex, site or stage of primary, volume of liver metastases, and alkaline phosphatase (ALP) or carcinoembryonic antigen (CEA) levels.
  • CONCLUSION: Of 37 patients initially treated palliatively for stage IV colorectal cancer, 92% required no surgical treatment of their primary.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis


98. Karoui M, Soprani A, Charachon A, Delbaldo C, Vigano L, Luciani A, Cherqui D: Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer. Eur J Surg Oncol; 2010 Jan;36(1):58-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer.
  • AIM: Management of patients with irresectable stage IV colorectal cancer is controversial.
  • Since 2000, we have favoured primary chemotherapy with stent insertion in case of obstructive tumor.
  • PATIENTS AND METHODS: From 2000 to 2007, 68 of 115 consecutive patients admitted with stage IV colorectal cancer were considered irresectable.
  • RESULTS: Of 68 patients, 37 received the intended primary chemotherapy, with stent insertion in 19, 13 required surgery as initial management and 18 patients received supportive care only.
  • Twelve patients in the primary chemotherapy group developed local complication, including bowel obstruction in 9, successfully managed by stent in 6 of them.
  • Median survival was 6.7 and 15.4 months for the whole series and patients treated by primary chemotherapy, respectively (p<0.0001).
  • On multivariate analysis, age, CEA level, primary chemotherapy and secondary curative resection were independently associated with survival.
  • CONCLUSION: In unselected patients with irresectable stage IV colorectal cancer, primary chemotherapy with or without stent is feasible in more than 50% of cases and is associated with a low rate of secondary surgery for complicated primary tumor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy. Female. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / therapy. Liver Neoplasms / secondary. Male. Middle Aged. Palliative Care. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19926243.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G: Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg; 2007 Jul;84(1):203-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after repeated resection of pulmonary metastases from colorectal cancer.
  • BACKGROUND: The purpose of this study was to evaluate the outcome of patients undergoing repeated resection of pulmonary metastases from colorectal cancer and specify factors promising long-term survival.
  • METHODS: From January 1993 to December 2003, 175 patients were diagnosed and resected for pulmonary metastases of colorectal cancer.
  • After reoperation, age, sex, primary tumor stage, preoperative carcinoembryonic antigen, disease-free interval, prior resection of liver metastases, and lymph node involvement were not found to be of prognostic importance.
  • CONCLUSIONS: Repeated resection of pulmonary metastases secondary to colorectal cancer is safe and can provide long-term survival for highly selected patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Prognosis. Reoperation. Retrospective Studies


100. Yang SZ, Dong JH, Li K, Zhang Y, Zhu J: Detection of AFPmRNA and melanoma antigen gene-1mRNA as markers of disseminated hepatocellular carcinoma cells in blood. Hepatobiliary Pancreat Dis Int; 2005 May;4(2):227-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Subjects included 65 patients with primary HCC, 22 patients with hepatitis B and liver cirrhosis, 12 patients with metastatic liver cancer, 11 patients with hepatic hemangioma, and 20 healthy volunteers.
  • The positive rate of AFPmRNA or MAGE-1mRNA was correlated with portal thrombosis, nodules of tumor, tumor diameter and TNM stage (P<0.05).
  • Samples from 4 (33.3%) of the 12 patients with metastatic liver cancer were MAGE-1mRNA positive, samples from 3(13.6%) of the 22 patients with cirrhosis AFPmRNA positive, and the others were both negative.
  • A two-marker RT-PCR assay with a liver-specific AFP marker and a cancer specific MAGE-1 marker may be a promising tool for detecting blood disseminated HCC cells with a better sensitivity and specificity than a single marker RT-PCR.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasm Proteins / blood. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Case-Control Studies. Cell Line, Tumor. Chi-Square Distribution. Cohort Studies. Female. Humans. Male. Melanoma-Specific Antigens. Middle Aged. Neoplastic Cells, Circulating. Probability. RNA, Messenger / analysis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908320.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MAGEA1 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  •  go-up   go-down






Advertisement